# Preclinical Alzheimer's disease: Definition, natural histo

Citation Report

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 1 | Cognitive Intervention As an Early Non-pharmacological Strategy in Alzheimer's Disease: A Translational Perspective. Frontiers in Aging Neuroscience, 2016, 8, 280. | 1.7 | 5 |
| 2 | Oleuropein Prevents Neuronal Death, Mitigates Mitochondrial Superoxide Production and Modulates Autophagy in a Dopaminergic Cellular Model. International Journal of Molecular Sciences, 2016, 17, 1293. | 1.8 | 43 |
| 3 | Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Molecular Medicine, 2016, 8, 1184-1196. | 3.3 | 219 |
| 4 | Domains of cognitive function in early old age: which ones are predicted by pre-retirement psychosocial work characteristics?. Occupational and Environmental Medicine, 2016, 73, 640-647. | 1.3 | 29 |
| 5 | Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. Journal of Alzheimer's Disease, 2016, 55, 19-35. | 1.2 | 35 |
| 6 | A$\beta$-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment. Expert Reviews in Molecular Medicine, 2016, 18, e13. | 1.6 | 34 |
| 7 | Spatial Patterns of Longitudinal Gray Matter Change as Predictors of Concurrent Cognitive Decline in Amyloid Positive Healthy Subjects. Journal of Alzheimer's Disease, 2016, 55, 343-358. | 1.2 | 10 |
| 8 | Recent advances in cerebrospinal fluid biomarkers for the detection of preclinical Alzheimer's disease. Current Opinion in Neurology, 2016, 29, 749-755. | 1.8 | 10 |
| 9 | Qualitative and quantitative assessment of self‐reported cognitive difficulties in nondemented elders: Association with medical help seeking, cognitive deficits, and $\beta$‐amyloid imaging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 5, 23-34. | 1.2 | 47 |
| 10 | La prevención de las demencias, un reto inmediato. Revista Clinica Espanola, 2016, 216, 483-484. | 0.2 | 0 |
| 11 | Alzheimer's disease: The use of contrast agents for magnetic resonance imaging to detect amyloid beta peptide inside the brain. Coordination Chemistry Reviews, 2016, 327-328, 27-34. | 9.5 | 27 |
| 12 | Pittsburgh compound B imaging and cerebrospinal fluid amyloid-$\beta$ in a multicentre European memory clinic study. Brain, 2016, 139, 2540-2553. | 3.7 | 107 |
| 13 | Biomarker-guided classification scheme of neurodegenerative diseases. Journal of Sport and Health Science, 2016, 5, 383-387. | 3.3 | 22 |
| 14 | Can Creutzfeldt-Jakob disease unravel the mysteries of Alzheimer?. Prion, 2016, 10, 369-376. | 0.9 | 6 |
| 15 | Cognitive Reserve and the Prevention of Dementia: the Role of Physical and Cognitive Activities. Current Psychiatry Reports, 2016, 18, 85. | 2.1 | 202 |
| 16 | ^{18}F-Labeled Benzyldiamine Derivatives as Novel Flexible Probes for Positron Emission Tomography of Cerebral $\beta$-Amyloid Plaques. Journal of Medicinal Chemistry, 2016, 59, 10577-10585. | 2.9 | 9 |
| 17 | Ageing, neurodegeneration and brain rejuvenation. Nature, 2016, 539, 180-186. | 13.7 | 787 |
| 18 | COMPASS: A computational model to predict changes in MMSE scores 24-months after initial assessment of Alzheimer's disease. Scientific Reports, 2016, 6, 34567. | 1.6 | 21 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 19 | Atrophy of amygdala and abnormal memory-related alpha oscillations over posterior cingulate predict conversion to Alzheimer's disease. Scientific Reports, 2016, 6, 31859. | 1.6 | 19 |
| 20 | Biomarkers, Genetics, and Epigenetic Studies to Explore the Neurocognitive Effects of Anesthesia in Children. Journal of Neurosurgical Anesthesiology, 2016, 28, 384-388. | 0.6 | 9 |
| 21 | Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife. Brain, 2016, 139, 2261-2274. | 3.7 | 41 |
| 22 | Quantitative MRI to understand Alzheimer's disease pathophysiology. Current Opinion in Neurology, 2016, 29, 437-444. | 1.8 | 37 |
| 23 | A commentary on Liang et Âal.'s paper with regard to emerging views of memory assessment in Alzheimer's disease. Cortex, 2017, 88, 198-200. | 1.1 | 6 |
| 24 | Monoaminergic neuropathology in Alzheimer's disease. Progress in Neurobiology, 2017, 151, 101-138. | 2.8 | 206 |
| 25 | Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 312-321. | 0.4 | 34 |
| 26 | Cognitive impairment and decline in cognitively normal older adults with high amyloid-$\beta$: A meta-analysis. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 108-121. | 1.2 | 131 |
| 27 | Associations of cumulative Pb exposure and longitudinal changes in Mini-Mental Status Exam scores, global cognition and domains of cognition: The VA Normative Aging Study. Environmental Research, 2017, 152, 102-108. | 3.7 | 38 |
| 28 | Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 143-151. | 1.2 | 57 |
| 29 | Tau PET imaging: present and future directions. Molecular Neurodegeneration, 2017, 12, 19. | 4.4 | 220 |
| 30 | Whole sight: clinical and research priorities in old age psychiatry. Lancet Psychiatry,the, 2017, 4, 94-95. | 3.7 | 3 |
| 31 | Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. Expert Review of Proteomics, 2017, 14, 285-299. | 1.3 | 78 |
| 32 | Visualization of neuritic plaques in Alzheimer's disease by polarization-sensitive optical coherence microscopy. Scientific Reports, 2017, 7, 43477. | 1.6 | 41 |
| 33 | Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept. Alzheimer's and Dementia, 2017, 13, 454-467. | 0.4 | 58 |
| 34 | Interaction between personality traits and cerebrospinal fluid biomarkers of Alzheimer's disease pathology modulates cognitive performance. Alzheimer's Research and Therapy, 2017, 9, 6. | 3.0 | 20 |
| 35 | A Precision Medicine Initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling. Climacteric, 2017, 20, 107-118. | 1.1 | 112 |
| 36 | Regional 18F-Fluorodeoxyglucose Hypometabolism is Associated with Higher Apathy Scores Over Time in Early Alzheimer Disease. American Journal of Geriatric Psychiatry, 2017, 25, 683-693. | 0.6 | 37 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 37 | The Role of Neuropsychology in the Assessment of the Cognitively Impaired Elderly. Neurologic Clinics, 2017, 35, 191-206. | 0.8 | 17 |
| 38 | Semantic memory and depressive symptoms in patients with subjective cognitive decline, mild cognitive impairment, and Alzheimer's disease. International Psychogeriatrics, 2017, 29, 1123-1135. | 0.6 | 17 |
| 39 | Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. Neurology, 2017, 88, 1814-1821. | 1.5 | 61 |
| 40 | Identification of changes in neuronal function as a consequence of aging and tauopathic neurodegeneration using a novel and sensitive magnetic resonance imaging approach. Neurobiology of Aging, 2017, 56, 78-86. | 1.5 | 23 |
| 41 | Detectable Neuropsychological Differences in Early Preclinical Alzheimer's Disease: A Meta-Analysis. Neuropsychology Review, 2017, 27, 305-325. | 2.5 | 76 |
| 42 | Chronic intermittent hypoxia induces oxidative stress and inflammation in brain regions associated with early-stage neurodegeneration. Physiological Reports, 2017, 5, e13258. | 0.7 | 121 |
| 43 | Serum Amino Acid Profiles in Normal Subjects and in Patients with or at Risk of Alzheimer Dementia. Dementia and Geriatric Cognitive Disorders Extra, 2017, 7, 143-159. | 0.6 | 50 |
| 44 | Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non–Alzheimer Disease Dementias. PET Clinics, 2017, 12, 351-359. | 1.5 | 21 |
| 45 | Age-specific and sex-specific prevalence of cerebral $\beta$-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50–95 years: a cross-sectional study. Lancet Neurology, The, 2017, 16, 435-444. | 4.9 | 241 |
| 46 | The *BDNF* Val66Met polymorphism moderates the effect of cognitive reserve on 36-month cognitive change in healthy older adults. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 323-331. | 1.8 | 15 |
| 47 | Association between naturally occurring antiamyloid $\beta$ autoantibodies and medial temporal lobe atrophy in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 96-97. | 0.9 | 1 |
| 48 | Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2017, 58, 939-950. | 1.2 | 74 |
| 49 | Influence of early maladaptive schemas, depression, and anxiety on the intensity of self-reported cognitive complaint in older adults with subjective cognitive decline. International Psychogeriatrics, 2017, 29, 1657-1667. | 0.6 | 17 |
| 50 | Early Detection of Learning Difficulties when Confronted with Novel Information in Preclinical Alzheimer's Disease Stage 1. Journal of Alzheimer's Disease, 2017, 58, 855-870. | 1.2 | 14 |
| 51 | Linking Amyloid-$\beta$ and Tau Deposition in Alzheimer Disease. JAMA Neurology, 2017, 74, 766. | 4.5 | 10 |
| 52 | Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study. Brain, 2017, 140, 1466-1485. | 3.7 | 132 |
| 53 | Targeting butyrylcholinesterase for preclinical single photon emission computed tomography (SPECT) imaging of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 166-176. | 1.8 | 19 |
| 54 | Early classification of Alzheimer's disease using hippocampal texture from structural MRI. Proceedings of SPIE, 2017, , . | 0.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------| 
| 55 | Minocycline reduces inflammatory parameters in the brain structures and serum and reverses memory impairment caused by the administration of amyloid β (1-42) in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 77, 23-31. | 2.5 | 71 |
| 56 | Metabolic Syndrome and the Cellular Phase of Alzheimer's Disease. Progress in Molecular Biology and Translational Science, 2017, 146, 243-258. | 0.9 | 56 |
| 57 | Direct and indirect cost of managing alzheimer's disease and related dementias in the United States. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 189-202. | 0.7 | 120 |
| 58 | Identifying memory impairment and early dementia in primary care. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 188-195. | 1.2 | 13 |
| 59 | The biomarker-based diagnosis of Alzheimer's disease. 2—lessons from oncology. Neurobiology of Aging, 2017, 52, 141-152. | 1.5 | 38 |
| 60 | Sleep changes without medial temporal lobe or brain cortical changes in community-dwelling individuals with subjective cognitive decline. Alzheimer's and Dementia, 2017, 13, 783-791. | 0.4 | 43 |
| 61 | The Amyloid-β Peptide in Amyloid Formation Processes: Interactions with Blood Proteins and Naturally Occurring Metal Ions. Israel Journal of Chemistry, 2017, 57, 674-685. | 1.0 | 21 |
| 62 | Mandibular movements and bite force in Alzheimer's disease before and after new denture insertion. Journal of Oral Rehabilitation, 2017, 44, 178-186. | 1.3 | 11 |
| 63 | Search for Alzheimer's disease biomarkers in blood cells: hypotheses-driven approach. Biomarkers in Medicine, 2017, 11, 917-931. | 0.6 | 47 |
| 64 | Alzheimer's disease prevention: from risk factors to early intervention. Alzheimer's Research and Therapy, 2017, 9, 71. | 3.0 | 424 |
| 65 | Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. JAMA Neurology, 2017, 74, 1481. | 4.5 | 77 |
| 66 | Higuchi fractal dimension of the electroencephalogram as a biomarker for early detection of Alzheimer's disease. , 2017, 2017, 2320-2324. | | 29 |
| 67 | Alzheimer's-related cortical atrophy is associated with postoperative delirium severity in persons without dementia. Neurobiology of Aging, 2017, 59, 55-63. | 1.5 | 28 |
| 68 | Measuring brain synaptic vesicle protein 2A with positron emission tomography and [$^{18}$F]UCB-H. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 481-486. | 1.8 | 47 |
| 69 | Polygenic hazard scores in preclinical Alzheimer disease. Annals of Neurology, 2017, 82, 484-488. | 2.8 | 49 |
| 70 | REST, a master regulator of neurogenesis, evolved under strong positive selection in humans and in non human primates. Scientific Reports, 2017, 7, 9530. | 1.6 | 27 |
| 71 | Association between LRP1 C766T polymorphism and Alzheimer's disease susceptibility: a meta-analysis. Scientific Reports, 2017, 7, 8435. | 1.6 | 7 |
| 72 | Differential diagnosis of Alzheimer's disease using spectrochemical analysis of blood. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E7929-E7938. | 3.3 | 125 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 73 | Subjective cognitive concerns are associated with objective memory performance in Caucasian but not African-American persons. Age and Ageing, 2017, 46, 988-993. | 0.7 | 44 |
| 74 | Dementia prevention, intervention, and care. Lancet, The, 2017, 390, 2673-2734. | 6.3 | 4,228 |
| 76 | Alzheimer's disease markers in the aged sheep (Ovis aries). Neurobiology of Aging, 2017, 58, 112-119. | 1.5 | 30 |
| 77 | Early functional network alterations in asymptomatic elders at risk for Alzheimer's disease. Scientific Reports, 2017, 7, 6517. | 1.6 | 64 |
| 78 | Absence of Neuropathology With Prolonged Isoflurane Sedation in Healthy Adult Rats. Journal of Neurosurgical Anesthesiology, 2017, 29, 439-447. | 0.6 | 6 |
| 79 | Nutritional Strategies in the Management of Alzheimer Disease: Systematic Review With Network Meta-Analysis. Journal of the American Medical Directors Association, 2017, 18, 897.e13-897.e30. | 1.2 | 23 |
| 80 | Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology‐based cohort. European Journal of Neurology, 2017, 24, 1326. | 1.7 | 71 |
| 81 | A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers. Journal of Alzheimer's Disease, 2017, 59, 1359-1379. | 1.2 | 65 |
| 82 | Immune and Imaging Correlates of Mild Cognitive Impairment Conversion to Alzheimer's Disease. Scientific Reports, 2017, 7, 16760. | 1.6 | 24 |
| 83 | Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities. Journal of Neuroscience, 2017, 37, 12263-12271. | 1.7 | 44 |
| 84 | Entorhinal tau pathology disrupts hippocampal-prefrontal oscillatory coupling during associative learning. Neurobiology of Aging, 2017, 58, 151-162. | 1.5 | 28 |
| 85 | Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurology, The, 2017, 16, 661-676. | 4.9 | 464 |
| 86 | Aβ seeding potency peaks in the early stages of cerebral β‐amyloidosis. EMBO Reports, 2017, 18, 1536-1544. | 2.0 | 38 |
| 87 | Revolution of Resting-State Functional Neuroimaging Genetics in Alzheimer's Disease. Trends in Neurosciences, 2017, 40, 469-480. | 4.2 | 34 |
| 88 | Memory performance-related dynamic brain connectivity indicates pathological burden and genetic risk for Alzheimer's disease. Alzheimer's Research and Therapy, 2017, 9, 24. | 3.0 | 43 |
| 89 | Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 58, 491-505. | 1.2 | 57 |
| 90 | Emerging ocular biomarkers of Alzheimer disease. Clinical and Experimental Ophthalmology, 2017, 45, 54-61. | 1.3 | 46 |
| 91 | Chronic Estradiol Administration During the Early Stage of Alzheimer's Disease Pathology Rescues Adult Hippocampal Neurogenesis and Ameliorates Cognitive Deficits in Aβ1-42 Mice. Molecular Neurobiology, 2017, 54, 7656-7669. | 1.9 | 21 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 92 | AÎ²-amyloid and Tau Imaging in Dementia. Seminars in Nuclear Medicine, 2017, 47, 75-88. | 2.5 | 96 |
| 93 | Subjective cognitive decline in cognitively normal elders from the community or from a memory clinic: Differential affective and imaging correlates. Alzheimer's and Dementia, 2017, 13, 550-560. | 0.4 | 135 |
| 94 | Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimerâ€™s Disease: Potential and Limitations. Molecular Neurobiology, 2017, 54, 5550-5562. | 1.9 | 119 |
| 95 | Incident Cerebral Microbleeds Detected by Susceptibility Weight-Imaging Help to Identify Patients with Mild Cognitive Impairment Progressing to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 60, 253-262. | 1.2 | 12 |
| 96 | BRain health and healthy AgeINg in retired rugby union players, the BRAIN Study: study protocol for an observational study in the UK. BMJ Open, 2017, 7, e017990. | 0.8 | 9 |
| 97 | Failure to Recover from Proactive Semantic Interference and Abnormal Limbic Connectivity in Asymptomatic, Middle-Aged Offspring of Patients with Late-Onset Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 60, 1183-1193. | 1.2 | 31 |
| 98 | Subjective Cognitive Complaints in Cognitively Healthy Older Adults and Their Relationship to Cognitive Performance and Depressive Symptoms. Journal of Alzheimer's Disease, 2017, 59, 871-881. | 1.2 | 56 |
| 99 | Spectroscopic imaging with spectral domain visible light optical coherence microscopy in Alzheimerâ€™s disease brain samples. Biomedical Optics Express, 2017, 8, 4007. | 1.5 | 51 |
| 100 | Associations of CAIDE Dementia Risk Score with MRI, PIB-PET measures, andÂcognition. Journal of Alzheimer's Disease, 2017, 59, 695-705. | 1.2 | 44 |
| 101 | Cerebrospinal Fluid Biomarkers in Alzheimerâ€™s Diseaseâ€"From Brain Starch to Bench and Bedside. Diagnostics, 2017, 7, 42. | 1.3 | 19 |
| 102 | Neuroanatomical and Neuropsychological Markers of Amnestic MCI: A Three-Year Longitudinal Study in Individuals Unaware of Cognitive Decline. Frontiers in Aging Neuroscience, 2017, 9, 34. | 1.7 | 13 |
| 103 | Relationship between Cognitive and Sleepâ€"wake Variables in Asymptomatic Offspring of Patients with Late-onset Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2017, 9, 93. | 1.7 | 14 |
| 104 | Functional Connectivity Disruption in Subjective Cognitive Decline and Mild Cognitive Impairment: A Common Pattern of Alterations. Frontiers in Aging Neuroscience, 2017, 9, 109. | 1.7 | 99 |
| 105 | Identification of Successful Cognitive Aging in the Alzheimerâ€™s Disease Neuroimaging Initiative Study. Journal of Alzheimer's Disease, 2017, 59, 101-111. | 1.2 | 28 |
| 106 | Early Prediction of Alzheimerâ€™s Disease Using Null Longitudinal Model-Based Classifiers. PLoS ONE, 2017, 12, e0168011. | 1.1 | 28 |
| 107 | Acute exercise does not modify brain activity and memory performance in APP/PS1 mice. PLoS ONE, 2017, 12, e0178247. | 1.1 | 18 |
| 108 | Differential deregulation of NGF and BDNF neurotrophins in a transgenic rat model of Alzheimer's disease. Neurobiology of Disease, 2017, 108, 307-323. | 2.1 | 66 |
| 109 | Altering neuronal excitability to preserve network connectivity in a computational model of Alzheimer's disease. PLoS Computational Biology, 2017, 13, e1005707. | 1.5 | 57 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 110 | On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimer's Research and Therapy, 2017, 9, 60. | 3.0 | 316 |
| 111 | Study partners should be required in preclinical Alzheimer's disease trials. Alzheimer's Research and Therapy, 2017, 9, 93. | 3.0 | 22 |
| 112 | Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer's disease patients from non-demented subjects. Oncotarget, 2017, 8, 16122-16143. | 0.8 | 122 |
| 113 | Cerebrospinal Fluid Biomarkers of Preclinical Alzheimer's Disease. Neuromethods, 2018, , 93-106. | 0.2 | 1 |
| 114 | Multimodal Neuroimaging in Alzheimer's Disease: Early Diagnosis, Physiopathological Mechanisms, and Impact of Lifestyle. Journal of Alzheimer's Disease, 2018, 64, S199-S211. | 1.2 | 54 |
| 115 | Characteristics of Cognitively Normal Mexican-Americans with Cognitive Complaints. Journal of Alzheimer's Disease, 2018, 61, 1485-1492. | 1.2 | 8 |
| 116 | Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment. Journal of Alzheimer's Disease, 2018, 64, S23-S31. | 1.2 | 11 |
| 117 | Interventional programmes to improve cognition during healthy and pathological ageing: Cortical modulations and evidence for brain plasticity. Ageing Research Reviews, 2018, 43, 81-98. | 5.0 | 72 |
| 118 | Age-accelerated cognitive decline in asymptomatic adults with CSF $\beta$-amyloid. Neurology, 2018, 90, e1306-e1315. | 1.5 | 42 |
| 119 | Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer's disease. Brain, 2018, 141, 1470-1485. | 3.7 | 109 |
| 120 | Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment. Movement Disorders, 2018, 33, 503-510. | 2.2 | 52 |
| 121 | Cognitive and neuroimaging features and brain $\beta$-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. Lancet Neurology, The, 2018, 17, 335-346. | 4.9 | 161 |
| 122 | Disentangling the biological pathways involved in early features of Alzheimer's disease in the Rotterdam Study. , 2018, 14, 848-857. | | 36 |
| 123 | Measurements of auto-antibodies to $\alpha$-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease. Journal of Neurochemistry, 2018, 145, 489-503. | 2.1 | 47 |
| 124 | Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloid-PET. Alzheimer's and Dementia, 2018, 14, 1088-1098. | 0.4 | 15 |
| 125 | Challenges associated with biomarker-based classification systems for Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 346-357. | 1.2 | 37 |
| 126 | Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. NeuroImage: Clinical, 2018, 19, 190-201. | 1.4 | 16 |
| 127 | NIA commentary on the NIA-AA Research Framework: Towards a biological definition of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 576-578. | 0.4 | 63 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 129 | NIAâ€AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 535-562. | 0.4 | 5,861 |
| 130 | Association of Plasma Neurofilament Light Chain with Neocortical Amyloid-Î² Load and Cognitive Performance in Cognitively Normal Elderly Participants. Journal of Alzheimer's Disease, 2018, 63, 479-487. | 1.2 | 50 |
| 131 | Shades of white: diffusion properties of T1- and FLAIR-defined white matter signal abnormalities differ in stages from cognitivelyÂnormal to dementia. Neurobiology of Aging, 2018, 68, 48-58. | 1.5 | 15 |
| 132 | The Rationale Behind the New Alzheimerâ€™s Disease Conceptualization: Lessons Learned During the Last Decades. Journal of Alzheimer's Disease, 2018, 62, 1067-1077. | 1.2 | 19 |
| 133 | Prevalence of preclinical Alzheimer disease. Neurology, 2018, 90, e1682-e1691. | 1.5 | 82 |
| 134 | Precision pharmacology for Alzheimerâ€™s disease. Pharmacological Research, 2018, 130, 331-365. | 3.1 | 79 |
| 135 | Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1021-1030. | 3.3 | 24 |
| 136 | Dementia. American Journal of Medicine, 2018, 131, 1161-1169. | 0.6 | 314 |
| 137 | Imaging tau and amyloid-Î² proteinopathies in Alzheimer disease and other conditions. Nature Reviews Neurology, 2018, 14, 225-236. | 4.9 | 321 |
| 138 | Novel Translational Research Methodology and the Prospect to a Better Understanding of Neurodegenerative Disease. Neurodegenerative Diseases, 2018, 18, 1-4. | 0.8 | 4 |
| 139 | Disposable <i>Morpho menelaus</i> Based Flexible Microfluidic and Electronic Sensor for the Diagnosis of Neurodegenerative Disease. Advanced Healthcare Materials, 2018, 7, 1701306. | 3.9 | 28 |
| 140 | Both hyper- and hypo-activation to cognitive challenge are associated with increased beta-amyloid deposition in healthy aging: A nonlinear effect. NeuroImage, 2018, 166, 285-292. | 2.1 | 30 |
| 141 | Regional association of pCASL-MRI with FDG-PET and PiB-PET in people at risk for autosomal dominant Alzheimer's disease. NeuroImage: Clinical, 2018, 17, 751-760. | 1.4 | 27 |
| 142 | Transcranial magnetic stimulation of the precuneus enhances memory and neural activity in prodromal Alzheimer's disease. NeuroImage, 2018, 169, 302-311. | 2.1 | 234 |
| 143 | Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults. American Journal of Psychiatry, 2018, 175, 530-537. | 4.0 | 175 |
| 144 | Dementia in Latin America. Neurology, 2018, 90, 222-231. | 1.5 | 124 |
| 145 | Behavioral and Neuropsychiatric Disorders in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 63, 899-910. | 1.2 | 40 |
| 146 | Cognitive medicine â€" a new approach in health care science. BMC Psychiatry, 2018, 18, 42. | 1.1 | 15 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 147 | White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. Alzheimer's Research and Therapy, 2018, 10, 30. | 3.0 | 40 |
| 148 | Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1470-1486. | 3.3 | 19 |
| 149 | The End of the Beginning of the Alzheimer's Disease Nightmare: A Devil's Advocate's View. Journal of Alzheimer's Disease, 2018, 64, S41-S46. | 1.2 | 12 |
| 150 | Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. JAMA Neurology, 2018, 75, 970. | 4.5 | 116 |
| 151 | Clinical utility of FDG-PET for the clinical diagnosis in MCI. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1497-1508. | 3.3 | 61 |
| 152 | Dissociable influences of *APOE* $\varepsilon$4 and polygenic risk of AD dementia on amyloid and cognition. Neurology, 2018, 90, e1605-e1612. | 1.5 | 71 |
| 153 | MR-guided delivery of AAV2-BDNF into the entorhinal cortex of non-human primates. Gene Therapy, 2018, 25, 104-114. | 2.3 | 32 |
| 154 | The personalized Alzheimer's disease cortical thickness index predicts likely pathology and clinical progression in mild cognitive impairment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 301-310. | 1.2 | 28 |
| 155 | Temporal unfolding of declining episodic memory on the Free and Cued Selective Reminding Test in the predementia phase of Alzheimer's disease: Implications for clinical trials. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 161-171. | 1.2 | 36 |
| 156 | Simultaneous quantitative susceptibility mapping and Flutemetamol-PET suggests local correlation of iron and $\beta$-amyloid as an indicator of cognitive performance at high age. NeuroImage, 2018, 174, 308-316. | 2.1 | 70 |
| 157 | Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. Journal of Alzheimer's Disease, 2018, 64, S47-S105. | 1.2 | 122 |
| 158 | FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain, 2018, 141, 1201-1217. | 3.7 | 67 |
| 159 | Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies. Nuclear Medicine and Molecular Imaging, 2018, 52, 24-30. | 0.6 | 13 |
| 160 | Cerebral hypoperfusion is not associated with an increase in amyloid $\beta$ pathology in middle-aged or elderly people. Alzheimer's and Dementia, 2018, 14, 54-61. | 0.4 | 21 |
| 161 | The Emergence of a New Conceptual Framework for Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 62, 1059-1066. | 1.2 | 56 |
| 162 | The Italian version of cognitive function instrument (CFI): reliability and validity in a cohort of healthy elderly. Neurological Sciences, 2018, 39, 111-118. | 0.9 | 16 |
| 163 | Characterizing biomarker features of cognitively normal individuals with ventriculomegaly. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 12-21. | 1.2 | 9 |
| 164 | Arterial stiffness, cognitive impairment and dementia: confounding factor or real risk?. Journal of Neurochemistry, 2018, 144, 527-548. | 2.1 | 74 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 165 | Alzheimer's disease. European Journal of Neurology, 2018, 25, 59-70. | 1.7 | 1,624 |
| 166 | Different Cognitive Complaint Profiles in Memory Clinic and Depressive Patients. American Journal of Geriatric Psychiatry, 2018, 26, 463-475. | 0.6 | 8 |
| 167 | Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds. Annals of Nuclear Medicine, 2018, 32, 75-86. | 1.2 | 45 |
| 168 | Cognitive reserve modulates attention processes in healthy elderly and amnestic mild cognitive impairment: An event-related potential study. Clinical Neurophysiology, 2018, 129, 198-207. | 0.7 | 36 |
| 169 | Increased midlife triglycerides predict brain $\beta$-amyloid and tau pathology 20 years later. Neurology, 2018, 90, e73-e81. | 1.5 | 76 |
| 170 | The Emerging Relationship Between Interstitial Fluid–Cerebrospinal Fluid Exchange, Amyloid-$\beta$, and Sleep. Biological Psychiatry, 2018, 83, 328-336. | 0.7 | 112 |
| 171 | Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease. Molecular Psychiatry, 2018, 23, 81-93. | 4.1 | 74 |
| 172 | Blood DNA methylation as a potential biomarker of dementia: A systematic review. Alzheimer's and Dementia, 2018, 14, 81-103. | 0.4 | 77 |
| 173 | Is use of the internet in midlife associated with lower dementia incidence? Results from the English Longitudinal Study of Ageing. Aging and Mental Health, 2018, 22, 1525-1533. | 1.5 | 27 |
| 174 | The Clinical Significance of Cognitive Interventions for the Patients with Mild Cognitive Impairment. Journal of Korean Neuropsychiatric Association, 2018, 57, 23. | 0.2 | 10 |
| 175 | Asymptomatic Carriers of Presenilin-1 E318G Variant Show no Cerebrospinal Fluid Biochemical Signs Suggestive of Alzheimer's disease in a Family with Late-onset Dementia. Current Alzheimer Research, 2018, 16, 1-7. | 0.7 | 4 |
| 176 | ANALYSIS OF THE RELATIONSHIP OF COGNITIVE IMPAIRMENT AND FUNCTIONAL IMPAIRMENT IN MILD ALZHEIMER'S DISEASE IN EXPEDITION 3. journal of prevention of Alzheimer's disease, The, 2018, 5, 1-4. | 1.5 | 5 |
| 177 | iPSC Modeling of Presenilin1 Mutation in Alzheimer's Disease with Cerebellar Ataxia. Experimental Neurobiology, 2018, 27, 350-364. | 0.7 | 25 |
| 178 | Imaging and Molecular Mechanisms of Alzheimer's Disease: A Review. International Journal of Molecular Sciences, 2018, 19, 3702. | 1.8 | 45 |
| 179 | Association between Hippocampal Shape, Neuroinflammation, and Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 66, 1131-1144. | 1.2 | 27 |
| 180 | Patient Engagement: The Fundació ACE Framework for Improving Recruitment and Retention in Alzheimer's Disease Research. Journal of Alzheimer's Disease, 2018, 62, 1079-1090. | 1.2 | 20 |
| 181 | European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS): study protocol. BMJ Open, 2018, 8, e021017. | 0.8 | 72 |
| 182 | Disorders of Body Weight, Sleep and Circadian Rhythm as Manifestations of Hypothalamic Dysfunction in Alzheimer's Disease. Frontiers in Cellular Neuroscience, 2018, 12, 471. | 1.8 | 31 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 183 | Alzheimer's disease in Down syndrome: An overlooked population for prevention trials. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 703-713. | 1.8 | 63 |
| 184 | Effects of Light Treatment on Sleep, Cognition, Mood, and Behavior in Alzheimer's Disease: A Systematic Review. Dementia and Geriatric Cognitive Disorders, 2018, 46, 371-384. | 0.7 | 91 |
| 185 | Associations of lifestyle and vascular risk factors with Alzheimer's brain biomarker changes during middle age: a 3-year longitudinal study in the broader New York City area. BMJ Open, 2018, 8, e023664. | 0.8 | 30 |
| 186 | The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Annals of Neurology, 2019, 85, 181-193. | 2.8 | 171 |
| 187 | Ethical Arguments Concerning the Use of Alzheimer's Disease Biomarkers in Individuals with No or Mild Cognitive Impairment: A Systematic Review and Framework for Discussion. Journal of Alzheimer's Disease, 2018, 66, 1309-1322. | 1.2 | 27 |
| 188 | Deep proteomic network analysis of Alzheimer's disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease. Molecular Neurodegeneration, 2018, 13, 52. | 4.4 | 178 |
| 189 | Telephone-based Dementia Screening I. , 2018, , . |  | 16 |
| 191 | Naming and verbal learning in adults with Alzheimer's disease, mild cognitive impairment and in healthy aging, with low educational levels. Arquivos De Neuro-Psiquiatria, 2018, 76, 93-99. | 0.3 | 2 |
| 192 | Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nature Neuroscience, 2018, 21, 1341-1349. | 7.1 | 289 |
| 193 | Radiomic Features of Hippocampal Subregions in Alzheimer's Disease and Amnestic Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2018, 10, 290. | 1.7 | 86 |
| 194 | Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. Brain, 2018, 141, 3233-3248. | 3.7 | 24 |
| 195 | Cortical thickness, brain metabolic activity, and in vivo amyloid deposition in asymptomatic, middle-aged offspring of patients with late-onset Alzheimer's disease. Journal of Psychiatric Research, 2018, 107, 11-18. | 1.5 | 16 |
| 196 | The role of cognitive reserve accumulated in midlife for the relation between chronic diseases and cognitive decline in old age: A longitudinal follow-up across six years. Neuropsychologia, 2018, 121, 37-46. | 0.7 | 34 |
| 197 | Systematic Review on Resting-State EEG for Alzheimer's Disease Diagnosis and Progression Assessment. Disease Markers, 2018, 2018, 1-26. | 0.6 | 195 |
| 198 | Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer's disease. Acta Neuropathologica, 2018, 136, 663-689. | 3.9 | 151 |
| 199 | Healthy Aging and Dementia: Two Roads Diverging in Midlife?. Frontiers in Aging Neuroscience, 2018, 10, 275. | 1.7 | 78 |
| 200 | Associations between Prospective and Retrospective Subjective Memory Complaints and Neuropsychological Performance in Older Adults: The Finger Study. Journal of the International Neuropsychological Society, 2018, 24, 1099-1109. | 1.2 | 11 |
| 201 | Understanding Epigenetics in the Neurodegeneration of Alzheimer's Disease: SAMP8 Mouse Model. Journal of Alzheimer's Disease, 2018, 62, 943-963. | 1.2 | 67 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 202 | Plasma Amyloid as Prescreener for the Earliest <scp>A</scp>lzheimer Pathological Changes. Annals of Neurology, 2018, 84, 648-658. | 2.8 | 230 |
| 203 | Disrupted interactions among the hippocampal, dorsal attention, and central‐executive networks in amnestic mild cognitive impairment. Human Brain Mapping, 2018, 39, 4987-4997. | 1.9 | 24 |
| 204 | The Role of Magnetoencephalography in the Early Stages of Alzheimer's Disease. Frontiers in Neuroscience, 2018, 12, 572. | 1.4 | 44 |
| 205 | "Exceptional brain aging" without Alzheimer's disease: triggers, accelerators, and the net sum game. Alzheimer's Research and Therapy, 2018, 10, 53. | 3.0 | 16 |
| 206 | Usefulness of Dual-Point Amyloid PET Scans in Appropriate Use Criteria: A Multicenter Study. Journal of Alzheimer's Disease, 2018, 65, 765-779. | 1.2 | 14 |
| 207 | Use of Flutemetamol F 18–Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment. JAMA Neurology, 2018, 75, 1114. | 4.5 | 75 |
| 208 | Interactive Associations of Vascular Risk and β-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals. JAMA Neurology, 2018, 75, 1124. | 4.5 | 165 |
| 209 | Neurocognitive disorders in ICD‐11: the debate and its outcome. World Psychiatry, 2018, 17, 229-230. | 4.8 | 12 |
| 210 | Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1487-1496. | 3.3 | 35 |
| 211 | Test-retest variability of resting-state networks in healthy aging and prodromal Alzheimer's disease. NeuroImage: Clinical, 2018, 19, 948-962. | 1.4 | 24 |
| 212 | Complexity Measures for Quantifying Changes in Electroencephalogram in Alzheimer's Disease. Complexity, 2018, 2018, 1-12. | 0.9 | 44 |
| 213 | Neuroprotective effects of INT-777 against Aβ1–42-induced cognitive impairment, neuroinflammation, apoptosis, and synaptic dysfunction in mice. Brain, Behavior, and Immunity, 2018, 73, 533-545. | 2.0 | 60 |
| 214 | Association of Motoric Cognitive Risk Syndrome with Cardiovascular Disease and Risk Factors: Results from an Original Study and Meta-Analysis. Journal of Alzheimer's Disease, 2018, 64, 875-887. | 1.2 | 33 |
| 215 | European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain <sup>18</sup>F‐fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. European Journal of Neurology, 2018, 25, 1201-1217. | 1.7 | 153 |
| 216 | Distinct Cognitive and Brain Morphological Features in Healthy Subjects Unaware of Informant-Reported Cognitive Decline. Journal of Alzheimer's Disease, 2018, 65, 181-191. | 1.2 | 15 |
| 217 | Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. Alzheimer's Research and Therapy, 2018, 10, 72. | 3.0 | 34 |
| 218 | Association of cerebrospinal fluid α‐synuclein with total and phospho‐tau<sub>181</sub> protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. Alzheimer's and Dementia, 2018, 14, 1623-1631. | 0.4 | 45 |
| 219 | Thinking-While-Moving Exercises May Improve Cognition in Elderly with Mild Cognitive Deficits: A Proof-of-Principle Study. Dementia and Geriatric Cognitive Disorders Extra, 2018, 8, 248-258. | 0.6 | 14 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 220 | Alzheimer's disease master regulators analysis: search for potential molecular targets and drug repositioning candidates. Alzheimer's Research and Therapy, 2018, 10, 59. | 3.0 | 80 |
| 221 | Cognitive Function and Brain Atrophy Predict Non-pharmacological Efficacy in Dementia: The Mihama-Kiho Scan Project2. Frontiers in Aging Neuroscience, 2018, 10, 87. | 1.7 | 13 |
| 222 | Potential Utility of Retinal Imaging for Alzheimer's Disease: A Review. Frontiers in Aging Neuroscience, 2018, 10, 188. | 1.7 | 52 |
| 223 | Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data. Frontiers in Aging Neuroscience, 2018, 10, 193. | 1.7 | 16 |
| 224 | The Quest for an Alzheimer Therapy. Frontiers in Neurology, 2018, 9, 108. | 1.1 | 19 |
| 225 | Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. Frontiers in Neuroscience, 2018, 12, 37. | 1.4 | 132 |
| 226 | An Algorithm for Preclinical Diagnosis of Alzheimer's Disease. Frontiers in Neuroscience, 2018, 12, 275. | 1.4 | 38 |
| 227 | A New Tool for Clinical Neuroscience—Synaptic Imaging. JAMA Neurology, 2018, 75, 1181. | 4.5 | 5 |
| 228 | The My Active and Healthy Aging (My-AHA) ICT platform to detect and prevent frailty in older adults: Randomized control trial design and protocol. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 252-262. | 1.8 | 17 |
| 229 | How the Brain Is Affected. , 2018, , 3-21. | | 0 |
| 230 | Early brain connectivity alterations and cognitive impairment in a rat model of Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 16. | 3.0 | 57 |
| 231 | Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. Alzheimer's Research and Therapy, 2018, 10, 45. | 3.0 | 11 |
| 232 | Patient Representation and Advocacy for Alzheimer Disease in Germany and Israel. Journal of Bioethical Inquiry, 2018, 15, 369-380. | 0.9 | 13 |
| 233 | The Proactive Patient: Long-Term Care Insurance Discrimination Risks of Alzheimer's Disease Biomarkers. Journal of Law, Medicine and Ethics, 2018, 46, 485-498. | 0.4 | 19 |
| 234 | Increasing beta-amyloid deposition in cognitively healthy aging predicts nonlinear change in BOLD modulation to difficulty. NeuroImage, 2018, 183, 142-149. | 2.1 | 10 |
| 235 | How early can we diagnose Alzheimer disease (and is it sufficient)?. Neurology, 2018, 91, 395-402. | 1.5 | 60 |
| 236 | Supragranular Pyramidal Cells Exhibit Early Metabolic Alterations in the 3xTg-AD Mouse Model of Alzheimer's Disease. Frontiers in Cellular Neuroscience, 2018, 12, 216. | 1.8 | 11 |
| 237 | The Head Turning Sign in Dementia and Mild Cognitive Impairment: Its Relationship to Cognition, Behavior, and Cerebrospinal Fluid Biomarkers. Dementia and Geriatric Cognitive Disorders, 2018, 46, 42-49. | 0.7 | 6 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 238 | Psychosocial interventions for Alzheimer's disease cognitive symptoms: a Bayesian network meta-analysis. BMC Geriatrics, 2018, 18, 175. | 1.1 | 67 |
| 239 | A 'Framingham-like' Algorithm for Predicting 4-Year Risk of Progression to Amnestic Mild Cognitive Impairment or Alzheimer's Disease Using Multidomain Information. Journal of Alzheimer's Disease, 2018, 63, 1383-1393. | 1.2 | 12 |
| 240 | Prophylactic and Therapeutic Applications of Catalytic Immunoglobulin Gene Delivery in a Mouse Model of Alzheimer's Disease. , 2018, , 139-161. | | 1 |
| 241 | Diagnostic and prognostic role of semantic processing in preclinical Alzheimer's disease. Biomarkers in Medicine, 2018, 12, 637-651. | 0.6 | 32 |
| 242 | Alterations in serum kynurenine pathway metabolites in individuals with high neocortical amyloid-$\beta$ load: A pilot study. Scientific Reports, 2018, 8, 8008. | 1.6 | 45 |
| 243 | Understanding the impact of sex and gender in Alzheimer's disease: A call to action. Alzheimer's and Dementia, 2018, 14, 1171-1183. | 0.4 | 468 |
| 244 | Estudios farmacogenéticos en la enfermedad de Alzheimer. Neurología, 2022, 37, 287-303. | 0.3 | 5 |
| 245 | Combining Cognitive, Genetic, and Structural Neuroimaging Markers to Identify Individuals with Increased Dementia Risk. Journal of Alzheimer's Disease, 2018, 64, 533-542. | 1.2 | 9 |
| 246 | The Patient with Cognitive Impairment. , 0, , 52-80. | | 1 |
| 247 | PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases. Neuroscience Letters, 2019, 691, 44-50. | 1.0 | 85 |
| 248 | Distinct disruptions in Land's cycle remodeling of glycerophosphocholines in murine cortex mark symptomatic onset and progression in two Alzheimer's disease mouse models. Journal of Neurochemistry, 2019, 149, 499-517. | 2.1 | 23 |
| 249 | Cannabinoid signalling in embryonic and adult neurogenesis: possible implications for psychiatric and neurological disorders. Acta Neuropsychiatrica, 2019, 31, 1-16. | 1.0 | 22 |
| 250 | Prediction of amyloid pathology in cognitively unimpaired individuals using voxel-wise analysis of longitudinal structural brain MRI. Alzheimer's Research and Therapy, 2019, 11, 72. | 3.0 | 23 |
| 251 | Longitudinal Association of Depression Symptoms With Cognition and Cortical Amyloid Among Community-Dwelling Older Adults. JAMA Network Open, 2019, 2, e198964. | 2.8 | 72 |
| 252 | Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study. Alzheimer's and Dementia, 2019, 15, 1208-1217. | 0.4 | 45 |
| 253 | Role of Resveratrol and Selenium on Oxidative Stress and Expression of Antioxidant and Anti-Aging Genes in Immortalized Lymphocytes from Alzheimer's Disease Patients. Nutrients, 2019, 11, 1764. | 1.7 | 69 |
| 254 | The current status of blood epigenetic biomarkers for dementia. Critical Reviews in Clinical Laboratory Sciences, 2019, 56, 435-457. | 2.7 | 21 |
| 255 | Changes in Centrality Frequency of the Default Mode Network in Individuals With Subjective Cognitive Decline. Frontiers in Aging Neuroscience, 2019, 11, 118. | 1.7 | 23 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 256 | Detecting Alzheimer's Disease from Continuous Speech Using Language Models. Journal of Alzheimer's Disease, 2019, 70, 1163-1174. | 1.2 | 19 |
| 257 | Quantitative Brain Amyloid Measures Predict Time-to-Progression from Amnestic Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 70, 477-486. | 1.2 | 4 |
| 258 | Air Pollution, Combustion and Friction Derived Nanoparticles, and Alzheimer's Disease in Urban Children and Young Adults. Journal of Alzheimer's Disease, 2019, 70, 343-360. | 1.2 | 23 |
| 259 | Alzheimer's disease drug development pipeline: 2019. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 272-293. | 1.8 | 546 |
| 260 | Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time. Alzheimer's Research and Therapy, 2019, 11, 61. | 3.0 | 30 |
| 261 | The role of hippocampal subfield volume and fornix microstructure in episodic memory across the lifespan. Hippocampus, 2019, 29, 1206-1223. | 0.9 | 30 |
| 262 | N-of-1 Clinical Trials in Nutritional Interventions Directed at Improving Cognitive Function. Frontiers in Nutrition, 2019, 6, 110. | 1.6 | 16 |
| 263 | Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set. Alzheimer's Research and Therapy, 2019, 11, 64. | 3.0 | 47 |
| 264 | Challenges in the treatment of Alzheimer's disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors. Expert Review of Neurotherapeutics, 2019, 19, 623-652. | 1.4 | 17 |
| 265 | Clinical Characteristics in Subjective Cognitive Decline with and without Worry: Baseline Investigation of the SILCODE Study. Journal of Alzheimer's Disease, 2019, 72, 443-454. | 1.2 | 25 |
| 266 | Future horizons in Alzheimer's disease research. Progress in Molecular Biology and Translational Science, 2019, 168, 223-241. | 0.9 | 19 |
| 267 | Cognition at age 70. Neurology, 2019, 93, e2144-e2156. | 1.5 | 37 |
| 268 | Associations Between the Subjective Cognitive Decline-Questionnaire's Scores, Gray Matter Volume, and Amyloid-$\beta$ Levels. Journal of Alzheimer's Disease, 2019, 72, 1287-1302. | 1.2 | 6 |
| 269 | When Does Alzheimer's Disease Really Start? The Role of Biomarkers. International Journal of Molecular Sciences, 2019, 20, 5536. | 1.8 | 57 |
| 270 | Tau and Amyloid-$\beta$ Pathology in Japanese Forensic Autopsy Series Under 40 Years of Age: Prevalence and Association with APOE Genotype and Suicide Risk. Journal of Alzheimer's Disease, 2019, 72, 641-652. | 1.2 | 8 |
| 271 | An electrochemical peptide-based biosensor for the Alzheimer biomarker amyloid-$\beta$(1–42) using a microporous gold nanostructure. Mikrochimica Acta, 2019, 186, 766. | 2.5 | 38 |
| 272 | Practical algorithms for amyloid $\beta$ probability in subjective or mild cognitive impairment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 710-720. | 1.2 | 8 |
| 273 | Low-Frequency Repetitive Transcranial Magnetic Stimulation of the Right Dorsolateral Prefrontal Cortex Enhances Recognition Memory in Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 72, 613-622. | 1.2 | 33 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 274 | Resting State Networks in the TgF344-AD Rat Model of Alzheimer's Disease Are Altered From Early Stages. Frontiers in Aging Neuroscience, 2019, 11, 213. | 1.7 | 16 |
| 275 | Biomarker-Based Signature of Alzheimer's Disease in Pre-MCI Individuals. Brain Sciences, 2019, 9, 213. | 1.1 | 15 |
| 277 | Visual short-term memory binding deficit with age-related hearing loss in cognitively normal older adults. Scientific Reports, 2019, 9, 12600. | 1.6 | 10 |
| 278 | Peripheral blood DNA methylation differences in twin pairs discordant for Alzheimer's disease. Clinical Epigenetics, 2019, 11, 130. | 1.8 | 29 |
| 279 | Case report: a giant arachnoid cyst masking Alzheimer's disease. BMC Psychiatry, 2019, 19, 274. | 1.1 | 7 |
| 280 | Aiginition Longitudinal Biomarker Investigation Of Neurodegeneration (ALBION): study design, cohort description, and preliminary data. Postgraduate Medicine, 2019, 131, 501-508. | 0.9 | 4 |
| 281 | Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer's disease. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1875-1881. | 1.4 | 20 |
| 282 | ABIDE Delphi study: topics to discuss in diagnostic consultations in memory clinics. Alzheimer's Research and Therapy, 2019, 11, 77. | 3.0 | 16 |
| 283 | Interaction between the progression of Alzheimer's disease and fractal degradation. Neurobiology of Aging, 2019, 83, 21-30. | 1.5 | 22 |
| 284 | Plasma lipocalin-2 levels in the preclinical stage of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 646-653. | 1.2 | 22 |
| 285 | Biomarker-guided clustering of Alzheimer's disease clinical syndromes. Neurobiology of Aging, 2019, 83, 42-53. | 1.5 | 48 |
| 286 | Perspective: Clinical relevance of the dichotomous classification of Alzheimer's disease biomarkers: Should there be a "gray zone"?. Alzheimer's and Dementia, 2019, 15, 1348-1356. | 0.4 | 20 |
| 287 | Permutation Entropy and Irreversibility in Gait Kinematic Time Series from Patients with Mild Cognitive Decline and Early Alzheimer's Dementia. Entropy, 2019, 21, 868. | 1.1 | 15 |
| 288 | Accelerated Ovarian Failure as a Unique Model to Study Peri-Menopause Influence on Alzheimer's Disease. Frontiers in Aging Neuroscience, 2019, 11, 242. | 1.7 | 25 |
| 289 | Regional brain atrophy predicts time to conversion to Alzheimer's disease, dependent on baseline volume. Neurobiology of Aging, 2019, 83, 86-94. | 1.5 | 20 |
| 290 | Age-Dependent Relationship Between Plasma $A\beta 40$ and $A\beta 42$ and Total Tau Levels in Cognitively Normal Subjects. Frontiers in Aging Neuroscience, 2019, 11, 222. | 1.7 | 29 |
| 291 | A Strategy for Discovery and Verification of Candidate Biomarkers in Cerebrospinal Fluid of Preclinical Alzheimer's Disease. Frontiers in Molecular Neuroscience, 2018, 11, 483. | 1.4 | 11 |
| 292 | A short perspective on the long road to effective treatments for Alzheimer's disease. British Journal of Pharmacology, 2019, 176, 3636-3648. | 2.7 | 17 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 293 | Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer's Disease and Related Dementias and Strategic Implications for Stakeholders. Journal of Alzheimer's Disease, 2019, 70, 323-341. | 1.2 | 146 |
| 294 | Differences in Subjective Cognitive Complaints Between Non-Demented Older Adults from a Memory Clinic and the Community. Journal of Alzheimer's Disease, 2019, 70, 61-73. | 1.2 | 6 |
| 295 | Dementia Detection and Classification from MRI Images Using Deep Neural Networks and Transfer Learning. Lecture Notes in Computer Science, 2019, , 925-933. | 1.0 | 8 |
| 296 | Multiscale Neuroscience of Psychiatric Disorders. Biological Psychiatry, 2019, 86, 512-522. | 0.7 | 46 |
| 297 | Subjective Cognitive Decline and Nighttime Sleep Alterations, a Longitudinal Analysis. Frontiers in Aging Neuroscience, 2019, 11, 142. | 1.7 | 18 |
| 298 | Disease signatures: Biomarkers/indicators of neurodegeneration. Molecular and Cellular Neurosciences, 2019, 97, 1-2. | 1.0 | 1 |
| 299 | The Italian version of Cognitive Function Instrument (CFI) for tracking changes in healthy elderly: results at 1-year follow-up. Neurological Sciences, 2019, 40, 2147-2153. | 0.9 | 8 |
| 300 | α-synuclein in the pathophysiology of Alzheimer's disease. Molecular Neurodegeneration, 2019, 14, 23. | 4.4 | 197 |
| 301 | Functional Connectivity Changes Across the Spectrum of Subjective Cognitive Decline, Amnestic Mild Cognitive Impairment and Alzheimer's Disease. Frontiers in Neuroinformatics, 2019, 13, 26. | 1.3 | 31 |
| 302 | Social Engagement and Amyloid-β-Related Cognitive Decline in Cognitively Normal Older Adults. American Journal of Geriatric Psychiatry, 2019, 27, 1247-1256. | 0.6 | 56 |
| 303 | Microbiota Alterations in Alzheimer's Disease: Involvement of the Kynurenine Pathway and Inflammation. Neurotoxicity Research, 2019, 36, 424-436. | 1.3 | 32 |
| 304 | Mild Cognitive Impairment with a High Risk of Progression to Alzheimer's Disease Dementia (MCI-HR-AD): Effect of Souvenaid® Treatment on Cognition and 18F-FDG PET Scans. Journal of Alzheimer's Disease Reports, 2019, 3, 95-102. | 1.2 | 8 |
| 305 | Multi-targeted ChEI-copper chelating molecules as neuroprotective agents. European Journal of Medicinal Chemistry, 2019, 174, 216-225. | 2.6 | 18 |
| 306 | A brief history of "Alzheimer disease". Neurology, 2019, 92, 1053-1059. | 1.5 | 52 |
| 307 | Association of Anticholinergic Use with Incidence of Alzheimer's Disease: Population-based Cohort Study. Scientific Reports, 2019, 9, 6802. | 1.6 | 20 |
| 308 | Gut Microbiota in Alzheimer's Disease, Depression, and Type 2 Diabetes Mellitus: The Role of Oxidative Stress. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-10. | 1.9 | 78 |
| 309 | Neuroimaging and Neurolaw: Drawing the Future of Aging. Frontiers in Endocrinology, 2019, 10, 217. | 1.5 | 5 |
| 310 | Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 303-309. | 1.1 | 53 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 311 | Clinical and Biomarker Characteristics According to Clinical Spectrum of Alzheimer's Disease (AD) in the Validation Cohort of Korean Brain Aging Study for the Early Diagnosis and Prediction of AD. Journal of Clinical Medicine, 2019, 8, 341. | 1.0 | 35 |
| 312 | Beta-blockers and salbutamol limited emotional memory disturbance and damage induced by orchiectomy in the rat hippocampus. Life Sciences, 2019, 224, 128-137. | 2.0 | 11 |
| 313 | A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment. CNS Drugs, 2019, 33, 251-263. | 2.7 | 115 |
| 314 | Ethical and social implications of using predictive modeling for Alzheimer's disease prevention: a systematic literature review protocol. BMJ Open, 2019, 9, e026468. | 0.8 | 3 |
| 315 | Lifespan Changes of the Human Brain In Alzheimer's Disease. Scientific Reports, 2019, 9, 3998. | 1.6 | 113 |
| 316 | Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's disease. NeuroImage: Clinical, 2019, 22, 101777. | 1.4 | 29 |
| 317 | Relationship between single nucleotide polymorphisms in the 3′UTR of amyloid precursor protein and risk of Alzheimer's disease and its mechanism. Bioscience Reports, 2019, 39, . | 1.1 | 22 |
| 318 | Synchrotron XRF imaging of Alzheimer's disease basal ganglia reveals linear dependence of high-field magnetic resonance microscopy on tissue iron concentration. Journal of Neuroscience Methods, 2019, 319, 28-39. | 1.3 | 10 |
| 319 | A blood-based signature of cerebrospinal fluid A$\beta$1–42 status. Scientific Reports, 2019, 9, 4163. | 1.6 | 21 |
| 321 | Chronic Angiotensin 1-7 Infusion Prevents Angiotensin-II-Induced Cognitive Dysfunction and Skeletal Muscle Injury in a Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 69, 297-309. | 1.2 | 18 |
| 322 | Nanowired delivery of cerebrolysin with neprilysin and p-Tau antibodies induces superior neuroprotection in Alzheimer's disease. Progress in Brain Research, 2019, 245, 145-200. | 0.9 | 30 |
| 323 | GABA and glutamate moderate beta-amyloid related functional connectivity in cognitively unimpaired old-aged adults. NeuroImage: Clinical, 2019, 22, 101776. | 1.4 | 28 |
| 324 | Alzheimer's Disease Including Focal Presentations. Seminars in Neurology, 2019, 39, 213-226. | 0.5 | 72 |
| 325 | Refining memory assessment of elderly people with cognitive impairment: Insights from the short-term memory binding test. Archives of Gerontology and Geriatrics, 2019, 83, 114-120. | 1.4 | 23 |
| 326 | Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease. Neurobiology of Aging, 2019, 79, 131-141. | 1.5 | 23 |
| 327 | The Importance of the Validation of M/EEG With Current Biomarkers in Alzheimer's Disease. Frontiers in Human Neuroscience, 2019, 13, 17. | 1.0 | 48 |
| 328 | The de-Alzheimerization of age-related dementias: implications for drug targets and approaches to effective therapeutics. Current Opinion in Pharmacology, 2019, 44, 62-75. | 1.7 | 8 |
| 329 | Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. Alzheimer's Research and Therapy, 2019, 11, 15. | 3.0 | 24 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 330 | Statistical considerations in a delayed€start design to demonstrate disease modification effect in neurodegenerative disorders. Pharmaceutical Statistics, 2019, 18, 407-419. | 0.7 | 3 |
| 331 | Increased cerebral blood volume in small arterial vessels is aÂcorrelate of amyloid-Î²â€"related cognitive decline. Neurobiology of Aging, 2019, 76, 181-193. | 1.5 | 10 |
| 332 | VisMET: a passive, efficient, and sensitive assessment of visuospatial memory in healthy aging, mild cognitive impairment, and Alzheimer's disease. Learning and Memory, 2019, 26, 93-100. | 0.5 | 28 |
| 333 | Motoric cognitive risk syndrome, incident cognitive impairment and morphological brain abnormalities: Systematic review and meta-analysis. Maturitas, 2019, 123, 45-54. | 1.0 | 38 |
| 334 | Classification of Subjective Cognitive Decline in Alzheimerâ€™s Disease Through Resting-State Hemodynamic Response Function. IOP Conference Series: Materials Science and Engineering, 2019, 612, 022020. | 0.3 | 0 |
| 335 | Ageing stereotypes and prodromal Alzheimerâ€™s disease (AGING): study protocol for an ongoing randomised clinical study. BMJ Open, 2019, 9, e032265. | 0.8 | 3 |
| 336 | Neuroprotective Function of Non-Proteolytic Amyloid-Î² Chaperones in Alzheimerâ€™s Disease. , 0, , . | | 2 |
| 337 | Primary Prevention of Alzheimerâ€™s Disease (AD). , 0, , . | | 0 |
| 338 | Sino Longitudinal Study on Cognitive Decline (SILCODE): protocol for a Chinese longitudinal observational study to develop risk prediction models of conversion to mild cognitive impairment in individuals with subjective cognitive decline. BMJ Open, 2019, 9, e028188. | 0.8 | 62 |
| 339 | Demencias degenerativas: Â¿un dilema de sÃndromes o de enfermedades?. NeurologÃa, 2019, , . | 0.3 | 0 |
| 340 | Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology. Neurology and Therapy, 2019, 8, 95-111. | 1.4 | 16 |
| 341 | Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study. BMJ Open, 2019, 9, e031947. | 0.8 | 35 |
| 342 | Elevated Plasma microRNA-206 Levels Predict Cognitive Decline and Progression to Dementia from Mild Cognitive Impairment. Biomolecules, 2019, 9, 734. | 1.8 | 41 |
| 343 | Brain metabolic connectome classify mild cognitive impairment into Alzheimerâ€™s dementia *. , 2019, 2019, 32-35. | | 1 |
| 344 | Plasma AÎ²42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study. Alzheimer's Research and Therapy, 2019, 11, 96. | 3.0 | 38 |
| 345 | The effects of repetitive transcranial magnetic stimulation in older adults with mild cognitive impairment: a protocol for a randomized, controlled three-arm trial. BMC Neurology, 2019, 19, 326. | 0.8 | 17 |
| 346 | Electrophysiological Characteristics of Mild Cognitive Impairment Patients during Semantic Memory Process. Journal of Korean Neuropsychiatric Association, 2019, 58, 353. | 0.2 | 0 |
| 347 | Critical Steps to be Taken into Consideration Before Quantification of Î²-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment. Neurology and Therapy, 2019, 8, 129-145. | 1.4 | 8 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 348 | Innovative Molecular Imaging for Clinical Research, Therapeutic Stratification, and Nosography in Neuroscience. Frontiers in Medicine, 2019, 6, 268. | 1.2 | 11 |
| 349 | Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research. Biomedicines, 2019, 7, 97. | 1.4 | 161 |
| 350 | Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria. Medicine (United States), 2019, 98, e16509. | 0.4 | 6 |
| 351 | Consensus statement on the neurocognitive outcomes for early detection of mild cognitive impairment and Alzheimer dementia from the Chinese Neuropsychological Normative (CN-NORM) Project. Journal of Global Health, 2019, 9, 020320. | 1.2 | 17 |
| 352 | Redox proteomics and amyloid Î²â€‘peptide: insights into Alzheimer disease. Journal of Neurochemistry, 2019, 151, 459-487. | 2.1 | 80 |
| 353 | Blood acetylcholinesterase level is a potential biomarker for the early detection of cerebral amyloid deposition in cognitively normal individuals. Neurobiology of Aging, 2019, 73, 21-29. | 1.5 | 29 |
| 354 | Retinol Binding Protein 4 Levels Are Not Altered in Preclinical Alzheimerâ€™s Disease and Not Associated with Cognitive Decline or Incident Dementia. Journal of Alzheimer's Disease, 2019, 67, 257-263. | 1.2 | 11 |
| 355 | Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. Molecular and Cellular Neurosciences, 2019, 97, 3-17. | 1.0 | 82 |
| 356 | Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. Alzheimer's and Dementia, 2019, 15, 292-312. | 0.4 | 310 |
| 357 | Healthy aging: A bibliometric analysis of the literature. Experimental Gerontology, 2019, 116, 93-105. | 1.2 | 15 |
| 358 | microRNA diagnostic panel for Alzheimerâ€™s disease and epigenetic trade-off between neurodegeneration and cancer. Ageing Research Reviews, 2019, 49, 125-143. | 5.0 | 87 |
| 359 | Blood-based redox-signature and their association to the cognitive scores in MCI and Alzheimerâ€™s disease patients. Free Radical Biology and Medicine, 2019, 130, 499-511. | 1.3 | 24 |
| 360 | Impact of Antidepressant Use on the Trajectory of Alzheimerâ€™s Disease: Evidence, Mechanisms, and Therapeutic Implications. CNS Drugs, 2019, 33, 17-29. | 2.7 | 7 |
| 361 | Prevalence and risk of progression of preclinical Alzheimerâ€™s disease stages: a systematic review and meta-analysis. Alzheimer's Research and Therapy, 2019, 11, 7. | 3.0 | 87 |
| 362 | Subjective memory complaints are associated with altered resting-state functional connectivity but not structural atrophy. NeuroImage: Clinical, 2019, 21, 101675. | 1.4 | 32 |
| 363 | Monocytes exposed to plasma from patients with Alzheimerâ€™s disease undergo metabolic reprogramming. Neuroscience Research, 2019, 148, 54-60. | 1.0 | 4 |
| 364 | Causes and Patterns of Dementia: An Update in the Era of Redefining Alzheimer's Disease. Annual Review of Public Health, 2019, 40, 65-84. | 7.6 | 94 |
| 365 | Identification and Preliminary Validation of a Plasma Profile Associated with Cognitive Decline in Dementia and At-Risk Individuals: A Retrospective Cohort Analysis. Journal of Alzheimer's Disease, 2019, 67, 327-341. | 1.2 | 32 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 366 | Key periods of cognitive decline in a nonhuman primate model of cognitive aging, the common marmoset (Callithrix jacchus). Neurobiology of Aging, 2019, 74, 1-14. | 1.5 | 37 |
| 367 | Molecular Pathogenesis of the Tauopathies. Annual Review of Pathology: Mechanisms of Disease, 2019, 14, 239-261. | 9.6 | 161 |
| 368 | Amyloid betaâ€"positive subjects exhibit longitudinal network-specific reductions in spontaneous brain activity. Neurobiology of Aging, 2019, 74, 191-201. | 1.5 | 6 |
| 369 | Brain Structural and Amyloid Correlates of Recovery From Semantic Interference in Cognitively Normal Individuals With or Without Family History of Late-Onset Alzheimerâ€™s Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2019, 31, 25-36. | 0.9 | 11 |
| 370 | Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome. Alzheimer's and Dementia, 2019, 15, 245-257. | 0.4 | 68 |
| 371 | Fluidâ€based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases. Journal of Neurochemistry, 2019, 151, 417-434. | 2.1 | 15 |
| 372 | ATP7B and Alzheimer Disease. , 2019, , 427-436. |  | 1 |
| 373 | Global White Matter Diffusion Characteristics Predict Longitudinal Cognitive Change Independently of Amyloid Status in Clinically Normal Older Adults. Cerebral Cortex, 2019, 29, 1251-1262. | 1.6 | 47 |
| 374 | Association of cerebrospinal fluid Neurogranin with Alzheimerâ€™s disease. Aging Clinical and Experimental Research, 2019, 31, 185-191. | 1.4 | 21 |
| 375 | Neuropsychiatric Symptoms as Risk Factors for Cognitive Decline in Clinically Normal Older Adults: The Cache County Study. American Journal of Geriatric Psychiatry, 2020, 28, 64-71. | 0.6 | 70 |
| 376 | Reduction of recruitment costs in preclinical AD trials: validation of automatic pre-screening algorithm for brain amyloidosis. Statistical Methods in Medical Research, 2020, 29, 151-164. | 0.7 | 30 |
| 377 | Quantifying brain metabolism from FDGâ€PET images into a probability of Alzheimer's dementia score. Human Brain Mapping, 2020, 41, 5-16. | 1.9 | 35 |
| 378 | Curcumin inhibits BACE1 expression through the interaction between ERÎ² and NFÎºB signaling pathway in SH-SY5Y cells. Molecular and Cellular Biochemistry, 2020, 463, 161-173. | 1.4 | 16 |
| 379 | Shared Latent Structures Between Imaging Features and Biomarkers in Early Stages of Alzheimer's Disease: A Predictive Study. IEEE Journal of Biomedical and Health Informatics, 2020, 24, 365-376. | 3.9 | 1 |
| 380 | The Impact of Estradiol on Neurogenesis and Cognitive Functions in Alzheimerâ€™s Disease. Cellular and Molecular Neurobiology, 2020, 40, 283-299. | 1.7 | 31 |
| 381 | Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. Alzheimer's and Dementia, 2020, 16, 262-272. | 0.4 | 47 |
| 382 | Evidence of a Relation Between Hippocampal Volume, White Matter Hyperintensities, and Cognition in Subjective Cognitive Decline and Mild Cognitive Impairment. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2020, 75, 1382-1392. | 2.4 | 39 |
| 383 | Workâ€related stress and cognitive performance among middleâ€aged adults: The Brazilian Longitudinal Study of Adult Health (ELSAâ€Brasil). Stress and Health, 2020, 36, 19-30. | 1.4 | 12 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 384 | The striatum, the hippocampus, and short-term memory binding: Volumetric analysis of the subcortical grey matter's role in mild cognitive impairment. NeuroImage: Clinical, 2020, 25, 102158. | 1.4 | 29 |
| 385 | Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning. Information Fusion, 2020, 58, 153-167. | 11.7 | 17 |
| 386 | Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age. Brain, 2020, 143, 320-335. | 3.7 | 100 |
| 387 | Plasma biomarkers of astrocytic and neuronal dysfunction in earlyâ€•and lateâ€•onset Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 681-695. | 0.4 | 143 |
| 388 | Therapeutic potential of targeting mixed lineage kinases in cancer and inflammation. , 2020, 207, 107457. | | 12 |
| 389 | Balance and Mobility Performance Along the Alzheimerâ€™s Disease Spectrum. Journal of Alzheimer's Disease, 2020, 73, 633-644. | 1.2 | 19 |
| 390 | Complexity changes in preclinical Alzheimerâ€™s disease: An MEG study of subjective cognitive decline and mild cognitive impairment. Clinical Neurophysiology, 2020, 131, 437-445. | 0.7 | 21 |
| 391 | The Spatial-Temporal Ordering of Amyloid Pathology and Opportunities for PET Imaging. Journal of Nuclear Medicine, 2020, 61, 166-171. | 2.8 | 38 |
| 392 | Decrease in 18F-Florbetapir Accumulation in the Cerebral Hemisphere With Hypoperfusion and Misery Perfusion Due to Chronic Atherosclerotic Occlusion of the Internal Carotid Artery. Clinical Nuclear Medicine, 2020, 45, e115-e116. | 0.7 | 1 |
| 393 | Altered verbal fluency processes in older adults with age-related hearing loss. Experimental Gerontology, 2020, 130, 110794. | 1.2 | 10 |
| 394 | Atrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimerâ€™s Disease. Cerebral Cortex, 2020, 30, 2083-2098. | 1.6 | 25 |
| 395 | New markers in Parkinson's disease. Advances in Clinical Chemistry, 2020, 96, 137-178. | 1.8 | 16 |
| 396 | Non-linear Relationship Between Plasma Amyloid-β 40 Level and Cognitive Decline in a Cognitively Normal Population. Frontiers in Aging Neuroscience, 2020, 12, 557005. | 1.7 | 3 |
| 397 | Multifactorial 10-Year Prior Diagnosis Prediction Model of Dementia. International Journal of Environmental Research and Public Health, 2020, 17, 6674. | 1.2 | 11 |
| 398 | Recent advances in research on Alzheimer's disease in China. Journal of Clinical Neuroscience, 2020, 81, 43-46. | 0.8 | 22 |
| 399 | An update on magnetic resonance imaging markers in AD. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642094798. | 1.5 | 6 |
| 401 | Alzheimer's disease: Recent treatment strategies. European Journal of Pharmacology, 2020, 887, 173554. | 1.7 | 300 |
| 402 | Fear about Alzheimerâ€™s disease among Israeli and German laypersons, persons with Mild Neurocognitive Disorder and their relatives: a qualitative study. International Psychogeriatrics, 2021, 33, 1019-1034. | 0.6 | 11 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 403 | Positron Emission Tomography (PET) and Neuroimaging in the Personalized Approach to Neurodegenerative Causes of Dementia. International Journal of Molecular Sciences, 2020, 21, 7481. | 1.8 | 16 |
| 404 | Caenorhabditis elegans as a possible model to screen anti-Alzheimer's therapeutics. Journal of Pharmacological and Toxicological Methods, 2020, 106, 106932. | 0.3 | 14 |
| 405 | Diagnostic and Prognostic Laboratory Testing for Alzheimer Disease. Clinics in Laboratory Medicine, 2020, 40, 289-303. | 0.7 | 2 |
| 406 | Preclinical models of disease and multimorbidity with focus upon cardiovascular disease and dementia. Mechanisms of Ageing and Development, 2020, 192, 111361. | 2.2 | 7 |
| 407 | Environmental and Cognitive Enrichment in Childhood as Protective Factors in the Adult and Aging Brain. Frontiers in Psychology, 2020, 11, 1814. | 1.1 | 16 |
| 408 | Primary Age-Related Tauopathy (PART): Addressing the Spectrum of Neuronal Tauopathic Changes in the Aging Brain. Current Neurology and Neuroscience Reports, 2020, 20, 39. | 2.0 | 24 |
| 409 | Passive immunotherapies targeting A$\beta$ and tau in Alzheimer's disease. Neurobiology of Disease, 2020, 144, 105010. | 2.1 | 81 |
| 410 | Quo vadis Alois?. Medicina Clínica (English Edition), 2020, 155, 491-493. | 0.1 | 0 |
| 411 | Fluid Candidate Biomarkers for Alzheimer's Disease: A Precision Medicine Approach. Journal of Personalized Medicine, 2020, 10, 221. | 1.1 | 20 |
| 412 | Health-related quality of life in people with predementia Alzheimer's disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review. Alzheimer's Research and Therapy, 2020, 12, 154. | 3.0 | 37 |
| 414 | Inflammaging in Endemic Areas for Infectious Diseases. Frontiers in Immunology, 2020, 11, 579972. | 2.2 | 16 |
| 415 | Cerebrospinal fluid $\alpha$-synuclein predicts neurodegeneration and clinical progression in non-demented elders. Translational Neurodegeneration, 2020, 9, 41. | 3.6 | 7 |
| 416 | Graph Theory Analysis Reveals Resting-State Compensatory Mechanisms in Healthy Aging and Prodromal Alzheimer's Disease. Frontiers in Aging Neuroscience, 2020, 12, 576627. | 1.7 | 34 |
| 417 | A method for assessing tissue respiration in anatomically defined brain regions. Scientific Reports, 2020, 10, 13179. | 1.6 | 22 |
| 418 | Role of Magnetoencephalography in the Early Stages of Alzheimer Disease. Neuroimaging Clinics of North America, 2020, 30, 217-227. | 0.5 | 9 |
| 419 | The Validation of Multifactor Model of Plasma A$\beta$42 and Total-Tau in Combination With MoCA for Diagnosing Probable Alzheimer Disease. Frontiers in Aging Neuroscience, 2020, 12, 212. | 1.7 | 18 |
| 420 | Combining Visual Rating Scales for Medial Temporal Lobe Atrophy and Posterior Atrophy to Identify Amnestic Mild Cognitive Impairment from Cognitively Normal Older Adults: Evidence Based on Two Cohorts. Journal of Alzheimer's Disease, 2020, 77, 323-337. | 1.2 | 9 |
| 421 | Role of Executive Functions in the Conversion from Mild Cognitive Impairment to Dementia. Journal of Alzheimer's Disease, 2020, 77, 641-653. | 1.2 | 29 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 422 | Health Outcome Prioritization in Alzheimer's Disease: Understanding the Ethical Landscape. Journal of Alzheimer's Disease, 2020, 77, 339-353. | 1.2 | 3 |
| 423 | Brain connectivity during Alzheimer's disease progression and its cognitive impact in a transgenic rat model. Network Neuroscience, 2020, 4, 397-415. | 1.4 | 12 |
| 424 | Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment. JAMA Neurology, 2020, 77, 1504. | 4.5 | 48 |
| 425 | Zinc Therapy in Early Alzheimer's Disease: Safety and Potential Therapeutic Efficacy. Biomolecules, 2020, 10, 1164. | 1.8 | 22 |
| 426 | Electroencephalogram Based Biomarkers for Detection of Alzheimer's Disease. , 0, , . | | 2 |
| 427 | Tau Imaging: New Era of Neuroimaging for Alzheimer's Disease. Nuclear Medicine and Molecular Imaging, 2020, 54, 161-162. | 0.6 | 4 |
| 428 | The Framing of "Alzheimer's Disease" Differences Between Scientific and Lay Literature and Their Ethical Implications. Gerontologist, The, 2021, 61, 746-755. | 2.3 | 13 |
| 429 | Association between concurrent antidepressant and hypnotic treatment and the risk of dementia: A nationwide cohort study. Journal of Affective Disorders, 2020, 277, 549-558. | 2.0 | 5 |
| 430 | Cognitive Dispersion Is Not Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Results from the European Prevention of Alzheimer's Dementia (EPAD) v500.0 Cohort. Journal of Alzheimer's Disease, 2020, 78, 185-194. | 1.2 | 5 |
| 431 | Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease. Molecular Neurodegeneration, 2020, 15, 55. | 4.4 | 107 |
| 432 | Amyloid PET imaging in clinical practice. Practical Neurology, 2020, 20, 451-462. | 0.5 | 28 |
| 433 | A Robust Blood-based Signature of Cerebrospinal Fluid $A\beta42$ Status. , 2020, 2020, 5523-5526. | | 3 |
| 434 | Decreased Alpha Reactivity from Eyes-Closed to Eyes-Open in Non-Demented Older Adults with Alzheimer's Disease: A Combined EEG and [18F]florbetaben PET Study. Journal of Alzheimer's Disease, 2020, 77, 1681-1692. | 1.2 | 4 |
| 435 | Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Sensitivity, Specificity and Potential for Clinical Use. Journal of Personalized Medicine, 2020, 10, 116. | 1.1 | 26 |
| 436 | An analytic framework for conceptualisations of disease: nine structuring questions and how some conceptualisations of Alzheimer's disease can lead to 'diseasisation'. Medicine, Health Care and Philosophy, 2020, 23, 677-693. | 0.9 | 2 |
| 437 | Advances in Non-Pharmacological Interventions for Subjective Cognitive Decline: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2020, 77, 903-920. | 1.2 | 10 |
| 438 | A Novel Metabolic Connectome Method to Predict Progression to Mild Cognitive Impairment. Behavioural Neurology, 2020, 2020, 1-9. | 1.1 | 7 |
| 439 | Increased Cerebrospinal Fluid Concentration of ZnT3 Is Associated with Cognitive Impairment in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 77, 1143-1155. | 1.2 | 13 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 440 | Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease. Acta Neuropathologica, 2020, 140, 463-476. | 3.9 | 34 |
| 441 | The preclinical amyloid sensitive composite to determine subtle cognitive differences in preclinical Alzheimer's disease. Scientific Reports, 2020, 10, 13583. | 1.6 | 7 |
| 442 | Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease‐modifying therapies. Alzheimer's and Dementia, 2020, 16, 1457-1468. | 0.4 | 43 |
| 443 | Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 99. | 3.0 | 22 |
| 444 | Associations of Green Tea Consumption and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study. Journal of Alzheimer's Disease, 2020, 77, 411-421. | 1.2 | 10 |
| 445 | Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's *continuum* when only subtle changes in Aβ pathology are detected. EMBO Molecular Medicine, 2020, 12, e12921. | 3.3 | 202 |
| 446 | Systemic inflammatory regulators and risk of Alzheimer's disease: a bidirectional Mendelian-randomization study. International Journal of Epidemiology, 2021, 50, 829-840. | 0.9 | 44 |
| 447 | Souvenaid for Alzheimer's disease. The Cochrane Library, 2020, 2020, CD011679. | 1.5 | 4 |
| 448 | Prevalence of Alzheimer's Disease and Parkinson's Disease in China: An Updated Systematical Analysis. Frontiers in Aging Neuroscience, 2020, 12, 603854. | 1.7 | 53 |
| 449 | The Destiny of Multiple Domain Amnesic Mild Cognitive Impairment: Effect of Alternative Neuropsychological Definitions and Their Adjunctive Role in Respect of Memory Impairment. Archives of Clinical Neuropsychology, 2021, 36, 702-710. | 0.3 | 3 |
| 450 | Quantitative informant‐and self‐reports of subjective cognitive decline predict amyloid beta PET outcomes in cognitively unimpaired individuals independently of age and APOE ε4. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12127. | 1.2 | 6 |
| 451 | Mitochondrial RNA in Alzheimer's Disease Circulating Extracellular Vesicles. Frontiers in Cell and Developmental Biology, 2020, 8, 581882. | 1.8 | 31 |
| 452 | Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Molecules, 2020, 25, 5789. | 1.7 | 935 |
| 453 | Cognitive, Genetic, Brain Volume, and Diffusion Tensor Imaging Markers as Early Indicators of Dementia. Journal of Alzheimer's Disease, 2020, 77, 1443-1453. | 1.2 | 7 |
| 454 | You Have Been Diagnosed with Alzheimer Disease; Is That It?. , 2020, , 110-112. | | 0 |
| 455 | Evolution of the Research Literature and the Scientific Community of Alzheimer's Disease from 1983-2017: A 35-Year Survey. Journal of Alzheimer's Disease, 2020, 75, 1105-1134. | 1.2 | 2 |
| 456 | Synthesis, bioactivity and binding energy calculations of novel 3-ethoxysalicylaldehyde based thiosemicarbazone derivatives. Bioorganic Chemistry, 2020, 100, 103924. | 2.0 | 27 |
| 457 | Quantifying and Describing the Natural History and Costs of Alzheimer's Disease and Effects of Hypothetical Interventions. Journal of Alzheimer's Disease, 2020, 75, 891-902. | 1.2 | 22 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 458 | Anodal Transcranial Direct Current Stimulation Can Improve Spatial Learning and Memory and Attenuate AÎ²42 Burden at the Early Stage of Alzheimerâ€™s Disease in APP/PS1 Transgenic Mice. Frontiers in Aging Neuroscience, 2020, 12, 134. | 1.7 | 31 |
| 459 | Cortical thickness computation by solving tetrahedron-based harmonic field. Computers in Biology and Medicine, 2020, 120, 103727. | 3.9 | 0 |
| 460 | A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer's disease. Neurobiology of Aging, 2020, 94, 60-70. | 1.5 | 35 |
| 461 | Sleep Quality and Health-Related Quality of Life in Older People With Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer Disease. Journal of Nervous and Mental Disease, 2020, 208, 387-396. | 0.5 | 19 |
| 462 | Engagement in Lifestyle Activities is Associated with Increased Alzheimerâ€™s Disease-Associated Cortical Thickness and Cognitive Performance in Older Adults. Journal of Clinical Medicine, 2020, 9, 1424. | 1.0 | 12 |
| 463 | Non-invasive Brain Stimulation in Alzheimer's Disease and Mild Cognitive Impairmentâ€”A State-of-the-Art Review on Methodological Characteristics and Stimulation Parameters. Frontiers in Human Neuroscience, 2020, 14, 179. | 1.0 | 35 |
| 464 | Looking for a Treatment for the Early Stage of Alzheimerâ€™s Disease: Preclinical Evidence with Co-Ultramicronized Palmitoylethanolamide and Luteolin. International Journal of Molecular Sciences, 2020, 21, 3802. | 1.8 | 24 |
| 465 | Evolution of white matter damage in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 722-732. | 1.7 | 16 |
| 466 | The effects of stress on cardiovascular disease and Alzheimer's disease: Physical exercise as a counteract measure. International Review of Neurobiology, 2020, 152, 157-193. | 0.9 | 3 |
| 467 | Sequences of cognitive decline in typical Alzheimer's disease and posterior cortical atrophy estimated using a novel eventâ€based model of disease progression. Alzheimer's and Dementia, 2020, 16, 965-973. | 0.4 | 30 |
| 468 | Pharmacogenetic studies in Alzheimer disease. NeurologÃa (English Edition), 2022, 37, 287-303. | 0.2 | 4 |
| 469 | The human olfactory system in two proteinopathies: Alzheimerâ€™s and Parkinsonâ€™s diseases. Translational Neurodegeneration, 2020, 9, 22. | 3.6 | 62 |
| 470 | Downregulated Platelet miR-1233-5p in Patients with Alzheimerâ€™s Pathologic Change with Mild Cognitive Impairment is Associated with AÎ²-Induced Platelet Activation via P-Selectin. Journal of Clinical Medicine, 2020, 9, 1642. | 1.0 | 10 |
| 471 | Evoked and induced EEG oscillations to visual targets reveal a differential pattern of change along the spectrum of cognitive decline in Alzheimer's Disease. International Journal of Psychophysiology, 2020, 155, 41-48. | 0.5 | 15 |
| 472 | Macular Thickness Decrease in Asymptomatic Subjects at High Genetic Risk of Developing Alzheimerâ€™s Disease: An OCT Study. Journal of Clinical Medicine, 2020, 9, 1728. | 1.0 | 22 |
| 473 | A typology of clinical conditions. Studies in History and Philosophy of Science Part C:Studies in History and Philosophy of Biological and Biomedical Sciences, 2020, 83, 101291. | 0.8 | 12 |
| 474 | The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment. Alzheimer's Research and Therapy, 2020, 12, 30. | 3.0 | 14 |
| 475 | Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12005. | 1.2 | 35 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 476 | Current and Future Treatments in Alzheimer Disease: An Update. Journal of Central Nervous System Disease, 2020, 12, 117957352090739. | 0.7 | 413 |
| 477 | Serum Hepcidin Levels in Cognitively Normal Older Adults with High Neocortical Amyloid-Î² Load. Journal of Alzheimer's Disease, 2020, 76, 291-301. | 1.2 | 3 |
| 478 | Effect of memantine on expression of Bace1-as and Bace1 genes in STZ-induced Alzheimeric rats. Molecular Biology Reports, 2020, 47, 5737-5745. | 1.0 | 5 |
| 479 | Ethical and Social Implications of Using Predictive Modeling for Alzheimerâ€™s Disease Prevention: A Systematic Literature Review. Journal of Alzheimer's Disease, 2020, 76, 923-940. | 1.2 | 5 |
| 480 | Extracellular vesicle biomarkers of Alzheimer's disease associated with subâ€clinical cognitive decline in late middle age. Alzheimer's and Dementia, 2020, 16, 1293-1304. | 0.4 | 53 |
| 481 | Initial Physician Experience with [18F]Flutemetamol Amyloid PET Imaging Following Availability for Routine Clinical Use in Japan. Journal of Alzheimer's Disease Reports, 2020, 4, 165-174. | 1.2 | 3 |
| 482 | APOE-amyloid interaction: Therapeutic targets. Neurobiology of Disease, 2020, 138, 104784. | 2.1 | 65 |
| 483 | PET Radiopharmaceuticals for Alzheimerâ€™s Disease and Parkinsonâ€™s Disease Diagnosis, the Current and Future Landscape. Molecules, 2020, 25, 977. | 1.7 | 68 |
| 484 | Cell and Tissue Instructive Materials for Central Nervous System Repair. Advanced Functional Materials, 2020, 30, 1909083. | 7.8 | 20 |
| 485 | Links Between Adiponectin and Dementia: From Risk Factors to Pathophysiology. Frontiers in Aging Neuroscience, 2019, 11, 356. | 1.7 | 11 |
| 486 | The characterisation of subjective cognitive decline. Lancet Neurology, The, 2020, 19, 271-278. | 4.9 | 627 |
| 487 | Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. Neurobiology of Aging, 2020, 89, 99-107. | 1.5 | 34 |
| 488 | The effect of age and obesity on platelet amyloid precursor protein processing and plasma markers of oxidative stress and inflammation. Experimental Gerontology, 2020, 132, 110838. | 1.2 | 8 |
| 489 | Social Cognition in Rehabilitation Context: Different Evolution of Affective and Cognitive Theory of Mind in Mild Cognitive Impairment. Behavioural Neurology, 2020, 2020, 1-9. | 1.1 | 16 |
| 490 | The Role of Macrophage Migration Inhibitory Factor in Alzheimerâ€²s Disease: Conventionally Pathogenetic or Unconventionally Protective?. Molecules, 2020, 25, 291. | 1.7 | 31 |
| 491 | Management of mild cognitive impairment (MCI): The need for national and international guidelines. World Journal of Biological Psychiatry, 2020, 21, 579-594. | 1.3 | 100 |
| 492 | Role of Fluid Biomarkers and PET Imaging in Early Diagnosis and its Clinical Implication in the Management of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease Reports, 2020, 4, 21-37. | 1.2 | 30 |
| 493 | Current understanding of metal ions in the pathogenesis of Alzheimerâ€™s disease. Translational Neurodegeneration, 2020, 9, 10. | 3.6 | 219 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 494 | Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?. Biochemical Pharmacology, 2020, 177, 113945. | 2.0 | 62 |
| 495 | Volunteering, polygenic risk for Alzheimer's disease, and cognitive functioning among older adults. Social Science and Medicine, 2020, 253, 112970. | 1.8 | 18 |
| 496 | Individual brain metabolic connectome indicator based on Kullback-Leibler Divergence Similarity Estimation predicts progression from mild cognitive impairment to Alzheimer's dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2753-2764. | 3.3 | 48 |
| 497 | Volumetric alterations in the hippocampal subfields of subjects at increased risk of dementia. Neurobiology of Aging, 2020, 91, 36-44. | 1.5 | 34 |
| 498 | Early diagnosis of Alzheimer's disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts. Clinical Neurophysiology, 2020, 131, 1287-1310. | 0.7 | 123 |
| 499 | Neuroimaging and analytical methods for studying the pathways from mild cognitive impairment to Alzheimer's disease: protocol for a rapid systematic review. Systematic Reviews, 2020, 9, 71. | 2.5 | 7 |
| 500 | Neural Correlates of Verb Fluency Performance in Cognitively Healthy Older Adults and Individuals With Dementia: A Pilot fMRI Study. Frontiers in Aging Neuroscience, 2020, 12, 73. | 1.7 | 20 |
| 501 | Early Detection of Alzheimer's Disease with Blood Plasma Proteins Using Support Vector Machines. IEEE Journal of Biomedical and Health Informatics, 2021, 25, 218-226. | 3.9 | 41 |
| 502 | Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. Neuropharmacology, 2021, 185, 108081. | 2.0 | 27 |
| 503 | Alzheimer's Disease and Parkinson Dementia Distinguished by Cognitive Marker. Archives of Clinical Neuropsychology, 2021, 36, 307-315. | 0.3 | 6 |
| 504 | Attitudes towards prediction and early diagnosis of late-onset dementia: a comparison of tested persons and family caregivers. Aging and Mental Health, 2021, 25, 832-843. | 1.5 | 18 |
| 505 | Blood neuro‐exosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage. Alzheimer's and Dementia, 2021, 17, 49-60. | 0.4 | 122 |
| 506 | Retinal imaging in Alzheimer's and neurodegenerative diseases. Alzheimer's and Dementia, 2021, 17, 103-111. | 0.4 | 89 |
| 507 | Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. Journal of the International Neuropsychological Society, 2021, 27, 426-438. | 1.2 | 30 |
| 508 | Therapeutic implications of hypothalamic-pituitaryadrenal-axis modulation in Alzheimer's disease: A narrative review of pharmacological and lifestyle interventions. Frontiers in Neuroendocrinology, 2021, 60, 100877. | 2.5 | 8 |
| 509 | A Multilevel View of the Development of Alzheimer's Disease. Neuroscience, 2021, 457, 283-293. | 1.1 | 43 |
| 510 | Dementia in Latin America: Paving the way toward a regional action plan. Alzheimer's and Dementia, 2021, 17, 295-313. | 0.4 | 68 |
| 511 | Detection of Alzheimer's Disease using cortical diffusion tensor imaging. Human Brain Mapping, 2021, 42, 967-977. | 1.9 | 22 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 512 | Mild Cognitive Impairment: the Manchester consensus. Age and Ageing, 2021, 50, 72-80. | 0.7 | 80 |
| 513 | A prospective cohort study of prodromal Alzheimer's disease: Prospective Imaging Study of Ageing: Genes, Brain and Behaviour (PISA). NeuroImage: Clinical, 2021, 29, 102527. | 1.4 | 19 |
| 514 | Cognitively oriented treatments in dementia. , 2021, , 15-34. | | 1 |
| 515 | Towards early disease modification of Parkinson's disease: a review of lessons learned in the Alzheimer field. Journal of Neurology, 2021, 268, 724-733. | 1.8 | 12 |
| 516 | Sleep and Tau Pathology in Vietnam War Veterans with Preclinical and Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease Reports, 2021, 5, 41-48. | 1.2 | 4 |
| 517 | Recurrent and concurrent patterns of regional BOLD dynamics and functional connectivity dynamics in cognitive decline. Alzheimer's Research and Therapy, 2021, 13, 28. | 3.0 | 15 |
| 518 | Future of the aging brain: Bridging the gap between research and policy. Aging Brain, 2021, 1, 100002. | 0.7 | 2 |
| 519 | Retinal imaging demonstrates reduced capillary density in clinically unimpaired <i>APOE</i> ε4 gene carriers. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12181. | 1.2 | 14 |
| 520 | Differences between memory encoding and retrieval failure in mild cognitive impairment: results from quantitative electroencephalography and magnetic resonance volumetry. Alzheimer's Research and Therapy, 2021, 13, 3. | 3.0 | 13 |
| 521 | Anserine, HClO-scavenger, protected against cognitive decline in individuals with mild cognitive impairment. Aging, 2021, 13, 1729-1741. | 1.4 | 14 |
| 522 | Legal Status and Dignity of Persons Living with Dementia in Serbia. Advances in Neuroethics, 2021, , 183-197. | 0.1 | 0 |
| 524 | Diagnóstico neuropsicológico diferencial en enfermedad de Alzheimer y demencia frontotemporal: una revisión sistemática cualitativa. Neurology Perspectives, 2021, 1, 82-97. | 0.2 | 3 |
| 525 | Open science datasets from PREVENT-AD, a longitudinal cohort of pre-symptomatic Alzheimer's disease. NeuroImage: Clinical, 2021, 31, 102733. | 1.4 | 42 |
| 526 | microRNAs as Early Biomarkers of Alzheimer's Disease: A Synaptic Perspective. Cells, 2021, 10, 113. | 1.8 | 37 |
| 527 | Learning Transition Times in Event Sequences: The Temporal Event-Based Model of Disease Progression. Lecture Notes in Computer Science, 2021, , 583-595. | 1.0 | 7 |
| 528 | EEG Biomarker for Alzheimer's Disease. , 0, , . | | 2 |
| 529 | The application of optical coherence tomography angiography in Alzheimer's disease: A systematic review. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12149. | 1.2 | 23 |
| 530 | A Western-style dietary pattern is associated with cerebrospinal fluid biomarker levels for preclinical Alzheimer's disease—A population-based cross-sectional study among 70-year-olds. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12183. | 1.8 | 11 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 531 | Anti-dementia Medication. , 2021, , 73-104. | | 0 |
| 532 | Diagnosis of Early Alzheimerâ€™s Disease: Clinical Practice in 2021. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-16. | 1.5 | 90 |
| 533 | Prevention of cognitive decline in subjective cognitive decline APOE Îµ4 carriers after EGCG and a multimodal intervention (PENSA): Study design. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12155. | 1.8 | 13 |
| 534 | Headâ€toâ€head comparison of amplified plasmonic exosome AÎ²42 platform and singleâ€molecule array immunoassay in a memory clinic cohort. European Journal of Neurology, 2021, 28, 1479-1489. | 1.7 | 11 |
| 535 | Alzheimerâ€™s Diseaseâ€"Molecular Defect, Public Perceptions and Stigma in South Africa. , 2021, , 63-99. | | 1 |
| 536 | The relationship of semantic intrusions to different etiological subtypes of MCI and cognitively healthy older adults. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12192. | 1.2 | 3 |
| 537 | Physical activity is associated with lower cerebral beta-amyloid and cognitive function benefits from lifetime experienceâ€"a study in exceptional aging. PLoS ONE, 2021, 16, e0247225. | 1.1 | 10 |
| 538 | Subclinical Atherosclerosis and Brain Metabolism in Middle-Aged Individuals. Journal of the American College of Cardiology, 2021, 77, 888-898. | 1.2 | 24 |
| 539 | Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2200-2211. | 3.3 | 19 |
| 540 | The search for a convenient procedure to detect one of the earliest signs of Alzheimer's disease: A systematic review of the prediction of brain amyloid status. Alzheimer's and Dementia, 2021, 17, 866-887. | 0.4 | 14 |
| 541 | Quantitative and Qualitative Analysis of Verb Fluency Performance in Individuals With Probable Alzheimer's Disease and Healthy Older Adults. American Journal of Speech-Language Pathology, 2021, 30, 481-490. | 0.9 | 10 |
| 542 | Features of Daily Social Interactions That Discriminate Between Older Adults With and Without Mild Cognitive Impairment. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2021, , . | 2.4 | 16 |
| 543 | Imaging Techniques in Alzheimerâ€™s Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring. International Journal of Molecular Sciences, 2021, 22, 2110. | 1.8 | 79 |
| 544 | TMSâ€"EEG Co-Registration in Patients with Mild Cognitive Impairment, Alzheimerâ€™s Disease and Other Dementias: A Systematic Review. Brain Sciences, 2021, 11, 303. | 1.1 | 16 |
| 545 | APOE-Îµ4 Carrier Status and Gut Microbiota Dysbiosis in Patients With Alzheimer Disease. Frontiers in Neuroscience, 2021, 15, 619051. | 1.4 | 30 |
| 546 | Associations of Salivary Total Antioxidant Capacity With Cortical Amyloid-Beta Burden, Cortical Glucose Uptake, and Cognitive Function in Normal Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 1839-1845. | 1.7 | 4 |
| 547 | Intranasal drug delivery for treatment of Alzheimerâ€™s disease. Drug Delivery and Translational Research, 2021, 11, 411-425. | 3.0 | 34 |
| 548 | Altered Insular Subregional Connectivity Associated With Cognitions for Distinguishing the Spectrum of Pre-clinical Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 597455. | 1.7 | 12 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 549 | Alterations in Dynamic Functional Connectivity in Individuals With Subjective Cognitive Decline. Frontiers in Aging Neuroscience, 2021, 13, 646017. | 1.7 | 23 |
| 550 | Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2157-2168. | 3.3 | 18 |
| 551 | The Impact of Estrogen and Estrogen-Like Molecules in Neurogenesis and Neurodegeneration: Beneficial or Harmful?. Frontiers in Cellular Neuroscience, 2021, 15, 636176. | 1.8 | 64 |
| 552 | Pharmacological inhibition of asparaginyl endopeptidase by δ-secretase inhibitor 11 mitigates Alzheimerâ€™s disease-related pathologies in a senescence-accelerated mouse model. Translational Neurodegeneration, 2021, 10, 12. | 3.6 | 9 |
| 553 | Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review. Frontiers in Aging Neuroscience, 2021, 13, 646901. | 1.7 | 16 |
| 554 | An Open Question: Is the A2A Adenosine Receptor a Novel Target for Alzheimerâ€™s Disease Treatment?. Frontiers in Pharmacology, 2021, 12, 652455. | 1.6 | 15 |
| 556 | A novel tauâ€based rhesus monkey model of Alzheimer's pathogenesis. Alzheimer's and Dementia, 2021, 17, 933-945. | 0.4 | 42 |
| 557 | Neuroproteomics: How a Multitude of Proteins Reflect Brain Functions. Biology Bulletin Reviews, 2021, 11, 143-153. | 0.3 | 0 |
| 558 | Can the RAVLT predict deterioration from MCI to dementia? Data from long term follow up. Experimental Aging Research, 2021, 47, 347-356. | 0.6 | 5 |
| 559 | Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimerâ€™s disease (MCI) Tj ETQq1 1 0.784314 rgBT /Ove | 2.7 | 77 |
| 560 | Performance evaluation of the mouse version of the LabPET II PET scanner. Physics in Medicine and Biology, 2021, 66, 065019. | 1.6 | 7 |
| 561 | Astrocytes in Alzheimerâ€™s Disease: Pathological Significance and Molecular Pathways. Cells, 2021, 10, 540. | 1.8 | 62 |
| 562 | Defining early changes in Alzheimerâ€™s disease from RNA sequencing of brain regions differentially affected by pathology. Scientific Reports, 2021, 11, 4865. | 1.6 | 23 |
| 563 | Research diagnostic criteria for Alzheimerâ€™s disease: findings from the LipiDiDiet randomized controlled trial. Alzheimer's Research and Therapy, 2021, 13, 64. | 3.0 | 6 |
| 564 | NMR-Based Metabolomics Approach to Explore Brain Metabolic Changes Induced by Prenatal Exposure to Autism-Inducing Chemicals. ACS Chemical Biology, 2021, 16, 753-765. | 1.6 | 13 |
| 565 | Exercise Training-Increased FBXO32 and FOXO1 in a Gender-Dependent Manner in Mild Cognitively Impaired African Americans: GEMS-1 Study. Frontiers in Aging Neuroscience, 2021, 13, 641758. | 1.7 | 5 |
| 566 | Prefrontal network dysfunctions in rapid eye movement sleep behavior disorder. Parkinsonism and Related Disorders, 2021, 85, 72-77. | 1.1 | 15 |
| 567 | Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. Brain Connectivity, 2021, 11, 239-249. | 0.8 | 18 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 568 | Theoretical impact of the AT(N) framework on dementia using a community autopsy sample. Alzheimer's and Dementia, 2021, 17, 1879-1891. | 0.4 | 5 |
| 569 | Western Diet Induces Impairment of Liver-Brain Axis Accelerating Neuroinflammation and Amyloid Pathology in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 654509. | 1.7 | 34 |
| 570 | Location and temporal memory of objects declines in aged marmosets (Callithrix jacchus). Scientific Reports, 2021, 11, 9138. | 1.6 | 10 |
| 571 | Empirically defining the preclinical stages of the Alzheimer's continuum in the Alzheimer's Disease Neuroimaging Initiative. Psychogeriatrics, 2021, 21, 491-502. | 0.6 | 6 |
| 572 | The application of a neuropsychological measure of executive working memory in older adults with memory impairment. Applied Neuropsychology Adult, 2021, , 1-10. | 0.7 | 1 |
| 573 | Surgery Performed Under Propofol Anesthesia Induces Cognitive Impairment and Amyloid Pathology in ApoE4 Knock-In Mouse Model. Frontiers in Aging Neuroscience, 2021, 13, 658860. | 1.7 | 16 |
| 574 | Alternative Targets to Fight Alzheimer's Disease: Focus on Astrocytes. Biomolecules, 2021, 11, 600. | 1.8 | 16 |
| 575 | An Effective Brain Imaging Biomarker for AD and aMCI: ALFF in Slow-5 Frequency Band. Current Alzheimer Research, 2021, 18, 45-55. | 0.7 | 14 |
| 576 | SIRT1-Dependent Upregulation of BDNF in Human Microglia Challenged with $A\hat{I}^2$: An Early but Transient Response Rescued by Melatonin. Biomedicines, 2021, 9, 466. | 1.4 | 16 |
| 577 | 2-(3-Hydroxybenzyl)benzo[d]isothiazol-3(2H)-one Mannich base derivatives as potential multifunctional anti-Alzheimer's agents. Medicinal Chemistry Research, 2021, 30, 1249-1264. | 1.1 | 2 |
| 578 | Mitochondrial dysfunction in Alzheimer's disease - a proteomics perspective. Expert Review of Proteomics, 2021, 18, 295-304. | 1.3 | 27 |
| 579 | Ego- and allo-network disconnection underlying spatial disorientation in subjective cognitive decline. Cortex, 2021, 137, 35-48. | 1.1 | 8 |
| 580 | Deep sparse graph functional connectivity analysis in AD patients using fMRI data. Computer Methods and Programs in Biomedicine, 2021, 201, 105954. | 2.6 | 3 |
| 581 | Biomarqueurs du liquide cérébrospinal. Pratique Neurologique - FMC, 2021, 12, 165-179. | 0.1 | 1 |
| 582 | Infectious Disease Burden and the Risk of Alzheimer's Disease: A Population-Based Study. Journal of Alzheimer's Disease, 2021, 81, 329-338. | 1.2 | 13 |
| 583 | Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain. Frontiers in Neuroscience, 2021, 15, 672954. | 1.4 | 19 |
| 584 | Impact of Cardiovascular Risk Factors in Adolescence, Young Adulthood, and Midlife on Late-Life Cognition: Study of Healthy Aging in African Americans. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 1692-1698. | 1.7 | 11 |
| 586 | Astrocyte subtype-specific approach to Alzheimer's disease treatment. Neurochemistry International, 2021, 145, 104956. | 1.9 | 10 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 587 | History in perspective: How Alzheimer's Disease came to be where it is?. Brain Research, 2021, 1758, 147342. | 1.1 | 8 |
| 588 | Multimodal measurement approach to identify individuals with mild cognitive impairment: study protocol for a cross-sectional trial. BMJ Open, 2021, 11, e046879. | 0.8 | 11 |
| 589 | Multifaceted Therapy of Nanocatalysts in Neurological Diseases. Journal of Biomedical Nanotechnology, 2021, 17, 711-743. | 0.5 | 4 |
| 590 | Personalizing the Care and Treatment of Alzheimer's Disease: An Overview. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 631-653. | 0.4 | 3 |
| 591 | Saccadic Eye Movement in Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis. Neuropsychology Review, 2022, 32, 193-227. | 2.5 | 36 |
| 592 | Insulin Resistance as a Common Link Between Current Alzheimer's Disease Hypotheses. Journal of Alzheimer's Disease, 2021, 82, 71-105. | 1.2 | 21 |
| 593 | Individualized Prediction of Early Alzheimer's Disease Based on Magnetic Resonance Imaging Radiomics, Clinical, and Laboratory Examinations: A 60‐Month Follow‐Up Study. Journal of Magnetic Resonance Imaging, 2021, 54, 1647-1657. | 1.9 | 14 |
| 594 | PET Agents in Dementia: An Overview. Seminars in Nuclear Medicine, 2021, 51, 196-229. | 2.5 | 23 |
| 595 | Degenerative dementias: a question of syndrome or disease?. Neurología (English Edition), 2021, , . | 0.2 | 0 |
| 596 | Î²-Amyloid in Cerebrospinal Fluid: How to Keep It Floating (Not Sticking) by Standardization of Preanalytic Processes and Collection Tubes. journal of applied laboratory medicine, The, 2021, 6, 1155-1164. | 0.6 | 3 |
| 597 | Alzheimer and Purinergic Signaling: Just a Matter of Inflammation?. Cells, 2021, 10, 1267. | 1.8 | 15 |
| 598 | Deciphering the links between psychological stress, depression, and neurocognitive decline in patients with Down syndrome. Neurobiology of Stress, 2021, 14, 100305. | 1.9 | 4 |
| 599 | Molecular imaging of beta-amyloid deposition in late-life depression. Neurobiology of Aging, 2021, 101, 85-93. | 1.5 | 15 |
| 601 | A Digital Twins Machine Learning Model for Forecasting Disease Progression in Stroke Patients. Applied Sciences (Switzerland), 2021, 11, 5576. | 1.3 | 14 |
| 602 | Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurology, The, 2021, 20, 484-496. | 4.9 | 396 |
| 603 | The Experts' Advice: Prevention and Responsibility in German Media and Scientific Discourses on Dementia. Qualitative Health Research, 2021, 31, 2005-2018. | 1.0 | 10 |
| 604 | A survey of brain network analysis by electroencephalographic signals. Cognitive Neurodynamics, 2022, 16, 17-41. | 2.3 | 26 |
| 605 | BACE1 controls synaptic function through modulating release of synaptic vesicles. Molecular Psychiatry, 2021, 26, 6394-6410. | 4.1 | 20 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 606 | The Impact of Study Setting on Clinical Characteristics in Older Chinese Adults with Subjective Cognitive Decline: Baseline Investigation of Convenience and Population-Based Samples. BioMed Research International, 2021, 2021, 1-9. | 0.9 | 4 |
| 607 | Sleep difficulties, incident dementia and allâ€cause mortality among older adults across 8Âyears: Findings from the National Health and Aging Trends Study. Journal of Sleep Research, 2021, 30, e13395. | 1.7 | 18 |
| 608 | ARCAM-1 Facilitates Fluorescence Detection of Amyloid-Containing Deposits in the Retina. Translational Vision Science and Technology, 2021, 10, 5. | 1.1 | 11 |
| 609 | The Role of High Triglycerides Level in Predicting Cognitive Impairment: A Review of Current Evidence. Nutrients, 2021, 13, 2118. | 1.7 | 36 |
| 610 | Pathological correlates of impaired self-awareness of memory function in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2021, 13, 118. | 3.0 | 7 |
| 611 | Local Functional MR Change Pattern and Its Association With Cognitive Function in Objectively-Defined Subtle Cognitive Decline. Frontiers in Aging Neuroscience, 2021, 13, 684918. | 1.7 | 19 |
| 612 | Protocol of the Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness cOhort (PRO) SubStudy. BMJ Open, 2021, 11, e043114. | 0.8 | 4 |
| 613 | Nutraceutical and Probiotic Approaches to Examine Molecular Interactions of the Amyloid Precursor Protein APP in Drosophila Models of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 7022. | 1.8 | 5 |
| 614 | Diseaseâ€specific interactome alterations via epichaperomics: the case for Alzheimerâ€™s disease. FEBS Journal, 2022, 289, 2047-2066. | 2.2 | 12 |
| 616 | Altered Functional Connectivity of the Basal Nucleus of Meynert in Subjective Cognitive Impairment, Early Mild Cognitive Impairment, and Late Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2021, 13, 671351. | 1.7 | 14 |
| 617 | Interplay between stress-related genes may influence Alzheimerâ€™s disease development: The results of genetic interaction analyses of human data. Mechanisms of Ageing and Development, 2021, 196, 111477. | 2.2 | 3 |
| 618 | Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimerâ€™s disease. Translational Psychiatry, 2021, 11, 356. | 2.4 | 34 |
| 619 | Retinal Ganglion Cells Functional Changes in a Mouse Model of Alzheimerâ€™s Disease Are Linked with Neurotransmitter Alterations. Journal of Alzheimer's Disease, 2021, 82, S5-S18. | 1.2 | 6 |
| 620 | The changing definition of Alzheimer's disease. Lancet Neurology, The, 2021, 20, 414-415. | 4.9 | 7 |
| 621 | Cognitively unimpaired individuals with a low burden of AÎ² pathology have a distinct CSF biomarker profile. Alzheimer's Research and Therapy, 2021, 13, 134. | 3.0 | 8 |
| 622 | The human connectome in Alzheimer disease â€" relationship to biomarkers and genetics. Nature Reviews Neurology, 2021, 17, 545-563. | 4.9 | 106 |
| 623 | Dysregulated protein phosphorylation: A determining condition in the continuum of brain aging and Alzheimer's disease. Brain Pathology, 2021, 31, e12996. | 2.1 | 33 |
| 624 | Machine learning for modeling the progression of Alzheimer disease dementia using clinical data: a systematic literature review. JAMIA Open, 2021, 4, ooab052. | 1.0 | 44 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 625 | Use of Deep-Learning Genomics to Discriminate Healthy Individuals from Those with Alzheimer's Disease or Mild Cognitive Impairment. Behavioural Neurology, 2021, 2021, 1-15. | 1.1 | 11 |
| 626 | Progression of Early Subclinical Atherosclerosis (PESA) Study. Journal of the American College of Cardiology, 2021, 78, 156-179. | 1.2 | 56 |
| 627 | A Primer on Hyperdimensional Computing for iEEG Seizure Detection. Frontiers in Neurology, 2021, 12, 701791. | 1.1 | 5 |
| 628 | Ethical Considerations in Dementia Diagnosis and Care. Neurology, 2021, 97, 80-89. | 1.5 | 12 |
| 629 | Past, present and future role of retinal imaging in neurodegenerative disease. Progress in Retinal and Eye Research, 2021, 83, 100938. | 7.3 | 60 |
| 630 | Moral motivation regarding dementia risk testing among affected persons in Germany and Israel. Journal of Medical Ethics, 2022, 48, 861-867. | 1.0 | 3 |
| 631 | Reasons for undergoing amyloid imaging among cognitively unimpaired older adults. Annals of Clinical and Translational Neurology, 2021, 8, 1646-1655. | 1.7 | 5 |
| 632 | Customized Application of tDCS for Clinical Rehabilitation in Alzheimer's Disease. Frontiers in Human Neuroscience, 2021, 15, 687968. | 1.0 | 1 |
| 633 | tDCS-Induced Memory Reconsolidation Effects and Its Associations With Structural and Functional MRI Substrates in Subjective Cognitive Decline. Frontiers in Aging Neuroscience, 2021, 13, 695232. | 1.7 | 11 |
| 634 | When Does Alzheimer's Disease Really Start? The Role of Biomarkers. Focus (American Psychiatric) Tj ETQq1 1 0.784314 rgBT /Overl | 0.4 | 1 |
| 635 | The Value of OCT and OCTA as Potential Biomarkers for Preclinical Alzheimer's Disease: A Review Study. Life, 2021, 11, 712. | 1.1 | 9 |
| 636 | Altered Gut Microbiota in Adults with Subjective Cognitive Decline: The SILCODE Study. Journal of Alzheimer's Disease, 2021, 82, 513-526. | 1.2 | 29 |
| 637 | Ethical aspects of facilitating the recruitment of people with dementia for clinical trials: A call for further debate. British Journal of Clinical Pharmacology, 2022, 88, 22-26. | 1.1 | 6 |
| 638 | Robust EEG Based Biomarkers to Detect Alzheimer's Disease. Brain Sciences, 2021, 11, 1026. | 1.1 | 11 |
| 639 | Dementia risk in the general population: large-scale external validation of prediction models in the AGES-Reykjavik study. European Journal of Epidemiology, 2021, 36, 1025-1041. | 2.5 | 5 |
| 641 | Longitudinal predictive modeling of tau progression along the structural connectome. NeuroImage, 2021, 237, 118126. | 2.1 | 8 |
| 642 | Electroacupuncture Improves Clearance of Amyloid-$\beta$ through the Glymphatic System in the SAMP8 Mouse Model of Alzheimer's Disease. Neural Plasticity, 2021, 2021, 1-11. | 1.0 | 13 |
| 643 | Chronic stress induces <scp>NPD</scp>-like behavior in <scp>APPPS1</scp> and <scp>WT</scp> mice with subtle differences in gene expression. Genes, Brain and Behavior, 2021, 20, e12766. | 1.1 | 4 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 644 | Association of Dipeptidyl Peptidase-4 Inhibitor Use and Amyloid Burden in Patients With Diabetes and AD-Related Cognitive Impairment. Neurology, 2021, 97, e1110-e1122. | 1.5 | 18 |
| 645 | What is the gold standard model for Alzheimer's disease drug discovery and development?. Expert Opinion on Drug Discovery, 2021, 16, 1415-1440. | 2.5 | 9 |
| 646 | Caracterização epidemiológica da mortalidade por Alzheimer no Brasil entre 2010 a 2019. Research, Society and Development, 2021, 10, e74101119316. | 0.0 | 1 |
| 647 | An Analysis of the Multifaceted Roles of Heme in the Pathogenesis of Cancer and Related Diseases. Cancers, 2021, 13, 4142. | 1.7 | 10 |
| 648 | Using Graphs in Processing of Light Microscope Medical Images. Mechanisms and Machine Science, 2022, , 127-156. | 0.3 | 1 |
| 650 | Association of Stress with Risk of Dementia and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2021, 82, 1573-1590. | 1.2 | 35 |
| 651 | Associations Between Cognitive Complaints, Memory Performance, Mood, and Amyloid-$\beta$ Accumulation in Healthy Amyloid Negative Late-Midlife Individuals. Journal of Alzheimer's Disease, 2021, 83, 127-141. | 1.2 | 4 |
| 652 | Imminent cognitive decline in normal elderly individuals is associated with hippocampal hyperconnectivity in the variant neural correlates of episodic memory. European Archives of Psychiatry and Clinical Neuroscience, 2021, , 1. | 1.8 | 1 |
| 653 | RNA Dynamics in Alzheimer's Disease. Molecules, 2021, 26, 5113. | 1.7 | 29 |
| 654 | Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease. Neurology and Therapy, 2021, 10, 919-940. | 1.4 | 25 |
| 655 | Awareness of Cognitive Decline in Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. Frontiers in Aging Neuroscience, 2021, 13, 697234. | 1.7 | 17 |
| 656 | Characteristics of Resting State EEG Power in 80+-Year-Olds of Different Cognitive Status. Frontiers in Aging Neuroscience, 2021, 13, 675689. | 1.7 | 6 |
| 657 | Diagnosi clinicolaboratoristica della malattia di Alzheimer. EMC - Neurologia, 2021, 21, 1-15. | 0.0 | 0 |
| 658 | Cognitive Function Assessment and Prediction for Subjective Cognitive Decline and Mild Cognitive Impairment. Brain Imaging and Behavior, 2022, 16, 645-658. | 1.1 | 8 |
| 659 | Microglia modulation with 1070-nm light attenuates A$\beta$ burden and cognitive impairment in Alzheimer's disease mouse model. Light: Science and Applications, 2021, 10, 179. | 7.7 | 46 |
| 660 | A$\beta$ initiates brain hypometabolism, network dysfunction and behavioral abnormalities via NOX2-induced oxidative stress in mice. Communications Biology, 2021, 4, 1054. | 2.0 | 23 |
| 662 | The influence of a 16-week exercise program, APOE status, and age on executive function task performance: A randomized trial. Experimental Gerontology, 2021, 152, 111431. | 1.2 | 9 |
| 664 | Influence of some climatic factors on tourism activities on Co To Island, Vietnam. International Journal of Advanced and Applied Sciences, 2021, 8, 50-57. | 0.2 | 3 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 666 | Systematic Search for Novel Circulating Biomarkers Associated with Extracellular Vesicles in Alzheimer's Disease: Combining Literature Screening and Database Mining Approaches. Journal of Personalized Medicine, 2021, 11, 946. | 1.1 | 6 |
| 667 | Ambient Air Pollution and Long-Term Trajectories of Episodic Memory Decline among Older Women in the WHIMS-ECHO Cohort. Environmental Health Perspectives, 2021, 129, 97009. | 2.8 | 5 |
| 668 | High Glycemic Diet Is Related to Brain Amyloid Accumulation Over One Year in Preclinical Alzheimer's Disease. Frontiers in Nutrition, 2021, 8, 741534. | 1.6 | 8 |
| 669 | Identifying individuals with Alzheimer's disease–like brains based on structural imaging in the Human Connectome Project Aging cohort. Human Brain Mapping, 2021, 42, 5535-5546. | 1.9 | 10 |
| 670 | Novelty detection-based approach for Alzheimer's disease and mild cognitive impairment diagnosis from EEG. Medical and Biological Engineering and Computing, 2021, 59, 2287-2296. | 1.6 | 17 |
| 671 | Random walks on B distributed resting-state functional connectivity to identify Alzheimer's disease and Mild Cognitive Impairment. Clinical Neurophysiology, 2021, 132, 2540-2550. | 0.7 | 5 |
| 672 | Apolipoprotein E4, amyloid, and cognition in Alzheimer's and Lewy body disease. Neurobiology of Aging, 2021, 106, 45-54. | 1.5 | 9 |
| 673 | Cobalt induces neurodegenerative damages through Pin1 inactivation in mice and human neuroglioma cells. Journal of Hazardous Materials, 2021, 419, 126378. | 6.5 | 25 |
| 674 | Functional co-activation of the default mode network in APOE Îµ4-carriers: A replication study. NeuroImage, 2021, 240, 118304. | 2.1 | 9 |
| 675 | Resting-state brain connectivity in healthy young and middle-aged adults at risk of progressive Alzheimer's disease. Neuroscience and Biobehavioral Reviews, 2021, 129, 142-153. | 2.9 | 18 |
| 676 | Moderately aged OFA rats as a novel model for mild age-related alterations in learning and memory. Brain and Cognition, 2021, 154, 105799. | 0.8 | 0 |
| 677 | GSK3Î² is involved in promoting Alzheimer's disease pathologies following chronic systemic exposure to Porphyromonas gingivalis lipopolysaccharide in amyloid precursor proteinNL-F/NL-F knock-in mice. Brain, Behavior, and Immunity, 2021, 98, 1-12. | 2.0 | 15 |
| 678 | Female specific risk factors for the development of Alzheimer's disease neuropathology and cognitive impairment: Call for a precision medicine approach. Ageing Research Reviews, 2021, 71, 101459. | 5.0 | 26 |
| 679 | The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease. Free Radical Biology and Medicine, 2021, 176, 16-33. | 1.3 | 53 |
| 680 | A mass spectrometric approach to study the interaction of amyloid Î² peptides with human Î±-2-macroglobulin. Biochimie, 2021, 191, 62-68. | 1.3 | 4 |
| 681 | BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCe project. Neurobiology of Aging, 2021, 108, 146-154. | 1.5 | 6 |
| 682 | Diagnostic biomarkers in Alzheimer's disease. Biomarkers in Neuropsychiatry, 2021, 5, 100041. | 0.7 | 12 |
| 683 | Memory Binding. , 2022, , 455-461. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 684 | Neuroepidemiology: New Methods, Results, and Challenges in the Definition of the Early Phases of Alzheimer's Disease: Insights From Subjective Memory Complaints and Subjective Cognitive Decline. , 2022, , 26-42. | | 0 |
| 685 | Potent Inhibitors of Cholinesterases: A Biochemical and In Silico Approach. Molecules, 2021, 26, 656. | 1.7 | 19 |
| 686 | Evaluation of the ATN model in a longitudinal memory clinic sample with different underlying disorders. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12031. | 1.2 | 9 |
| 687 | Analysis of Serum miRNAs in Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2021, 36, 153331752110217. | 0.9 | 14 |
| 688 | Classification of Brain MR Images for the Diagnosis of Alzheimer's Disease Based on Features Extracted from the Three Main Brain Tissues. Smart Innovation, Systems and Technologies, 2021, , 212-219. | 0.5 | 0 |
| 689 | The role of astrocyte‐mediated plasticity in neural circuit development and function. Neural Development, 2021, 16, 1. | 1.1 | 78 |
| 690 | What patients want to know, and what we actually tell them: The ABIDE project. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12113. | 1.8 | 9 |
| 691 | Epidemiology and Risk Factors of Alzheimer's Disease: A Focus on Diet. Neuromethods, 2018, , 15-42. | 0.2 | 7 |
| 692 | Systems Biology Methods for Alzheimer's Disease Research Toward Molecular Signatures, Subtypes, and Stages and Precision Medicine: Application in Cohort Studies and Trials. Methods in Molecular Biology, 2018, 1750, 31-66. | 0.4 | 36 |
| 693 | The Technology-Enhanced Ability Continuum-of-Care Home Program for People with Cognitive Disorders: Concept Design and Scenario of Use. Lecture Notes of the Institute for Computer Sciences, Social-Informatics and Telecommunications Engineering, 2018, , 64-73. | 0.2 | 4 |
| 694 | Prediction of Amyloidosis from Neuropsychological and MRI Data for Cost Effective Inclusion of Pre-symptomatic Subjects in Clinical Trials. Lecture Notes in Computer Science, 2017, , 357-364. | 1.0 | 1 |
| 695 | Demenz. , 2017, , 1377-1465. | | 1 |
| 696 | Diagnostics and Treatments of Iron-Related CNS Diseases. Advances in Experimental Medicine and Biology, 2019, 1173, 179-194. | 0.8 | 9 |
| 697 | Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 131-138. | 1.2 | 93 |
| 698 | Neuroinflammation in pathogenesis of Alzheimer's disease: Phytochemicals as potential therapeutics. Mechanisms of Ageing and Development, 2020, 189, 111259. | 2.2 | 36 |
| 700 | Beyond episodic memory: Semantic processing as independent predictor of hippocampal/perirhinal volume in aging and mild cognitive impairment due to Alzheimer's disease.. Neuropsychology, 2019, 33, 523-533. | 1.0 | 18 |
| 701 | Language Performance of Individuals at Risk for Mild Cognitive Impairment. Journal of Speech, Language, and Hearing Research, 2019, 62, 706-722. | 0.7 | 30 |
| 702 | Transcranial magnetic stimulation reveals diminished homoeostatic metaplasticity in cognitively impaired adults. Brain Communications, 2020, 2, fcaa203. | 1.5 | 11 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 708 | Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias. Functional Neurology, 2016, 31, 205-215. | 1.3 | 35 |
| 709 | Assessment of pathological features in Alzheimer's disease brain tissue with a large field-of-view visible-light optical coherence microscope. Neurophotonics, 2018, 5, 1. | 1.7 | 20 |
| 710 | Alzheimer's Disease: Many Failed Trials, So Where Do We Go from Here?. Journal of Investigative Medicine, 2020, 68, 1135-1140. | 0.7 | 17 |
| 711 | Biomarker Testing: Piercing the Fog of Alzheimer's and Related Dementia. Biomedicine Hub, 2020, 5, 1-22. | 0.4 | 7 |
| 712 | Late-onset Alzheimer Disease. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 14-33. | 0.4 | 70 |
| 713 | PRECISION MEDICINE - THE GOLDEN GATE FOR DETECTION, TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE. journal of prevention of Alzheimer's disease, The, 2016, 3, 1-17. | 1.5 | 67 |
| 714 | 'ALZHEIMER'S PROGRESSION SCORE': DEVELOPMENT OF A BIOMARKER SUMMARY OUTCOME FOR AD PREVENTION TRIALS. journal of prevention of Alzheimer's disease, The, 2016, 3, 1-7. | 1.5 | 12 |
| 715 | ALZHEIMER'S DISEASE COMPOSITE SCORE: A POST-HOC ANALYSIS USING DATA FROM THE LIPIDIDIET TRIAL IN PRODROMAL ALZHEIMER'S DISEASE. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-5. | 1.5 | 10 |
| 716 | Comparative Analysis of Different Definitions of Amyloid-β Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-10. | 1.5 | 9 |
| 717 | Resting State BOLD Variability of the Posterior Medial Temporal Lobe Correlates with Cognitive Performance in Older Adults with and without Risk for Cognitive Decline. ENeuro, 2020, 7, ENEURO.0290-19.2020. | 0.9 | 18 |
| 718 | Prodromes and Preclinical Detection of Brain Diseases: Surveying the Ethical Landscape of Predicting Brain Health. ENeuro, 2019, 6, ENEURO.0439-18.2019. | 0.9 | 9 |
| 719 | Dietary interventions and cognition of Alzheimer's disease patients: a systematic review of randomized controlled trial. Dementia E Neuropsychologia, 2020, 14, 258-282. | 0.3 | 14 |
| 720 | Detecting dementia in. , 2019, , . | | 7 |
| 721 | Multilingual prediction of. , 2019, , . | | 5 |
| 722 | Genome-wide association study of cerebrospinal fluid neurofilament light levels in non-demented elders. Annals of Translational Medicine, 2019, 7, 657-657. | 0.7 | 15 |
| 723 | A Systematic Review of Current Progresses in the Nucleic Acid-Based Therapies for Neurodegeneration with Implications for Alzheimer's Disease. Mini-Reviews in Medicinal Chemistry, 2020, 20, 1499-1517. | 1.1 | 14 |
| 724 | Genetic Variants and Oxidative Stress in Alzheimer's Disease. Current Alzheimer Research, 2020, 17, 208-223. | 0.7 | 23 |
| 725 | Pre-Mild Cognitive Impairment: Can Visual Memory Predict Who Rapidly Convert to Mild Cognitive Impairment?. Psychiatry Investigation, 2018, 15, 869-875. | 0.7 | 15 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 726 | Comparison Global Brain Volume Ratios on Alzheimer's Disease Using 3D T1 Weighted MR Images. European Journal of Science and Technology, 0, , 599-606. | 0.5 | 4 |
| 727 | Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease. Dialogues in Clinical Neuroscience, 2019, 21, 177-191. | 1.8 | 17 |
| 728 | Subjective and Objective Mental and Physical Functions Affect Subjective Cognitive Decline in Community-Dwelling Elderly Japanese People. Healthcare (Switzerland), 2020, 8, 347. | 1.0 | 4 |
| 729 | Amyloid β and free heme: bloody new insights into the pathogenesis of Alzheimer's disease. Neural Regeneration Research, 2018, 13, 1170. | 1.6 | 25 |
| 731 | Neuroimaging in Dementia: A Brief Review. Cureus, 2020, 12, e8682. | 0.2 | 13 |
| 732 | Determinants of Cognitive Trajectories in Normal Aging: A Longitudinal PET-MRI Study in a Community-based Cohort. Current Alzheimer Research, 2021, 18, 482-491. | 0.7 | 3 |
| 733 | Engineering extracellular vesicles for Alzheimer's disease: An emerging cell-free approach for earlier diagnosis and treatment. WIREs Mechanisms of Disease, 2022, 14, e1541. | 1.5 | 3 |
| 734 | Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Mild Cognitive Impairment: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Human Neuroscience, 2021, 15, 723715. | 1.0 | 11 |
| 735 | Proposed diagnostic criteria for mild cognitive impairment in Down syndrome population. Journal of Applied Research in Intellectual Disabilities, 2022, 35, 495-505. | 1.3 | 5 |
| 736 | Parkinsonism and motor neuron disorders: Lessons from Western Pacific ALS/PDC. Journal of the Neurological Sciences, 2022, 433, 120021. | 0.3 | 12 |
| 737 | proNGF Measurement in Cerebrospinal Fluid Samples of a Large Cohort of Living Patients With Alzheimer's Disease by a New Automated Immunoassay. Frontiers in Aging Neuroscience, 2021, 13, 741414. | 1.7 | 2 |
| 738 | Comorbidity Trajectories Associated With Alzheimer's Disease: A Matched Case-Control Study in a United States Claims Database. Frontiers in Neuroscience, 2021, 15, 749305. | 1.4 | 10 |
| 739 | Disruption of Glucose Metabolism in Aged Octodon degus: A Sporadic Model of Alzheimer's Disease. Frontiers in Integrative Neuroscience, 2021, 15, 733007. | 1.0 | 2 |
| 740 | Dopamine, sleep, and neuronal excitability modulate amyloid-β–mediated forgetting in Drosophila. PLoS Biology, 2021, 19, e3001412. | 2.6 | 4 |
| 741 | PET Imaging of Tau Pathology and Amyloid-β, and MRI for Alzheimer's Disease Feature Fusion and Multimodal Classification. Journal of Alzheimer's Disease, 2021, 84, 1497-1514. | 1.2 | 5 |
| 742 | Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services—part 4 of 6. Alzheimer's Research and Therapy, 2021, 13, 171. | 3.0 | 37 |
| 743 | Rethinking modeling Alzheimer's disease progression from a multi-task learning perspective with deep recurrent neural network. Computers in Biology and Medicine, 2021, 138, 104935. | 3.9 | 14 |
| 744 | Dementia and Bioethics. Mental Health and Illness Worldwide, 2016, , 1-13. | 0.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 745 | Demenz. , 2016, , 1-89. | | 0 |
| 746 | Neuropsychiatric Symptoms in Cognitive Impairment and Dementia: A Brief Introductory Overview. Neuropsychiatric Symptoms of Neurological Disease, 2017, , 1-7. | 0.3 | 0 |
| 747 | Dementia and Bioethics. Mental Health and Illness Worldwide, 2017, , 141-153. | 0.1 | 0 |
| 748 | Welcome note for special issue â€œClinical Diagnosis of Alzheimerâ€™s diseaseâ€. JBR Journal of Clinical Diagnosis and Research, 2017, 05, . | 0.1 | 0 |
| 750 | A Narrative Review of Natural History of Diseases and Continuity of Care in Family Medicine. Archives of Community Medicine and Public Health, 0, , 041-047. | 0.1 | 1 |
| 751 | Few-mode fiber detection for tissue characterization in optical coherence tomography. , 2017, , . | | 1 |
| 754 | Clinical Meaningfulness of Biomarker Endpoints in Alzheimerâ€™s Disease Research. Neuromethods, 2018, , 235-248. | 0.2 | 0 |
| 755 | Multidimensional Dynamics of the Proteome in the Neurodegenerating and Ageing Mammalian Brain. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 756 | The Ethics of Biomarker-Based Preclinical Diagnosis of Alzheimerâ€™s Disease. Neuromethods, 2018, , 249-258. | 0.2 | 2 |
| 757 | Imagerie mÃ©tabolique et molÃ©culaire : lâ€™exemple des maladies neurodÃ©gÃ©nÃ©ratives. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 1511-1521. | 0.0 | 0 |
| 758 | Postponing Cognitive Decline. Practical Issues in Geriatrics, 2019, , 117-127. | 0.3 | 0 |
| 762 | Latest Developments in Preclinical Alzheimerâ€™s Disease. US Neurology, 2019, 15, 12. | 0.2 | 0 |
| 766 | Assessment of Memory Impairment in Early Diagnosis of Alzheimerâ€™s Disease. Current Alzheimer Research, 2019, 16, 975-985. | 0.7 | 5 |
| 767 | Mild Cognitive Impairment and Early Dementia. , 2020, , 215-236. | | 0 |
| 768 | Nighttime hypoxia affects global cognition, memory, and executive function in community-dwelling individuals with hypertension. Journal of Clinical Sleep Medicine, 2020, 16, 243-250. | 1.4 | 3 |
| 769 | Optimizing Modifiable and Lifestyle-related Factors in the Prevention of Dementia Disorders with Special Reference to Alzheimer, Parkinson and Autism Diseases. Current Nutrition and Food Science, 2020, 16, 900-911. | 0.3 | 2 |
| 772 | A Review of Brain-Targeted Nonviral Gene-Based Therapies for the Treatment of Alzheimerâ€™s Disease. Molecular Pharmaceutics, 2021, 18, 4237-4255. | 2.3 | 5 |
| 774 | Advances in Modeling Alzheimer's Disease In Vitro. Advanced NanoBiomed Research, 2021, 1, 2100097. | 1.7 | 10 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 776 | Transcranial Magnetic Stimulation in Dementia: From Pathophysiology to Treatment. , 2020, , 161-173. | | 0 |
| 777 | APOE Genotypes and Brain Imaging Classes in Normal Cognition, Mild Cognitive Impairment, and Alzheimer's Disease: A Longitudinal Study. Current Alzheimer Research, 2020, 17, 766-780. | 0.7 | 3 |
| 778 | Â¿Quo vadis Alois?. Medicina ClÃnica, 2020, 155, 491-493. | 0.3 | 0 |
| 779 | Genetic Discrimination in the United States: What State and National Government Are Doing to Protect Personal Information. Ius Comparatum, 2020, , 331-354. | 0.1 | 0 |
| 780 | Is Reluctance to Share Alzheimer's Disease Biomarker Status with a Study Partner a Barrier to Preclinical Trial Recruitment?. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-7. | 1.5 | 3 |
| 781 | Applying the Alzheimer Disease ATN Diagnostic Framework in Atypical Dementia. Alzheimer Disease and Associated Disorders, 2020, 34, 357-359. | 0.6 | 3 |
| 782 | CaracterizaciÃ³n de pacientes con demencia de tipo Alzheimer precoz vs tardÃo. Acta Medica Colombiana: AMC: Organo De La Asociacion Columbiana De Medicina Interna, 2020, 45, . | 0.0 | 0 |
| 783 | The Relationship between Inflammation, Cognitive Impairments, and Neuroimaging Data in Schizophrenia. Neuroscience and Behavioral Physiology, 2021, 51, 873-881. | 0.2 | 2 |
| 784 | Amyloid and Tau in Alzheimer's Disease: Biomarkers or Molecular Targets for Therapy? Are We Shooting the Messenger?. American Journal of Psychiatry, 2021, 178, 1014-1025. | 4.0 | 11 |
| 786 | Couple and family interventions for high mortality health conditions: A strategic review (2010–2019). Journal of Marital and Family Therapy, 2021, , . | 0.6 | 8 |
| 787 | Ranking convolutional neural network for Alzheimer's disease mini-mental state examination prediction at multiple time-points. Computer Methods and Programs in Biomedicine, 2022, 213, 106503. | 2.6 | 15 |
| 788 | Integrated Positron Emission Tomography/Magnetic Resonance Imaging in clinical diagnosis of Alzheimer's disease. European Journal of Radiology, 2021, 145, 110017. | 1.2 | 14 |
| 790 | Human Brain Disorders: A Review. The Open Biology Journal, 2020, 8, 6-21. | 0.5 | 6 |
| 791 | Impact of the New Conceptual Framework of Alzheimer's Disease in Imaging Studies. , 2021, , 427-451. | | 0 |
| 792 | Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs. Innovations in Clinical Neuroscience, 2017, 14, 22-29. | 0.1 | 34 |
| 793 | Correlation of vascular change and cognitive impairment in age-related macular degeneration patients. American Journal of Translational Research (discontinued), 2021, 13, 336-348. | 0.0 | 0 |
| 794 | Exploring brain glucose metabolic patterns in cognitively normal adults at risk of Alzheimer's disease: A cross-validation study with Chinese and ADNI cohorts. NeuroImage: Clinical, 2022, 33, 102900. | 1.4 | 8 |
| 795 | A Comparative Study of Functional Connectivity Measures for Brain Network Analysis in the Context of AD Detection with EEG. Entropy, 2021, 23, 1553. | 1.1 | 9 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 796 | Application of Sebum Lipidomics to Biomarkers Discovery in Neurodegenerative Diseases. Metabolites, 2021, 11, 819. | 1.3 | 11 |
| 797 | Quâ€™apporte lâ€™imagerie hybride TEP-IRM dans lâ€™Ã©tude des pathologies neuro-dÃ©gÃ©nÃ©rativesÂ?. Bulletin De L'Academie Nationale De Medecine, 2021, 206, 28-28. | 0.0 | 0 |
| 798 | Pursuit of precision medicine: Systems biology approaches in Alzheimer's disease mouse models. Neurobiology of Disease, 2021, 161, 105558. | 2.1 | 10 |
| 799 | Antisense oligonucleotides for Alzheimer's disease therapy: from the mRNA to miRNA paradigm. EBioMedicine, 2021, 74, 103691. | 2.7 | 33 |
| 800 | Plasma pâ€tau$_{181}$ shows stronger network association to Alzheimer's disease dementia than neurofilament light and total tau. Alzheimer's and Dementia, 2022, 18, 1523-1536. | 0.4 | 18 |
| 801 | Targeting Systemic Innate Immune Cells as a Therapeutic Avenue for Alzheimer Disease. Pharmacological Reviews, 2022, 74, 1-17. | 7.1 | 23 |
| 802 | Can exercise training teach us how to treat Alzheimerâ€™s disease?. Ageing Research Reviews, 2022, 75, 101559. | 5.0 | 23 |
| 803 | Lower serum testosterone concentrations are associated with a higher incidence of dementia in men: The UK Biobank prospective cohort study. Alzheimer's and Dementia, 2022, 18, 1907-1918. | 0.4 | 19 |
| 804 | Discriminating speech traits of Alzheimer's disease assessed through a corpus of reading task for Spanish language. Computer Speech and Language, 2022, 73, 101341. | 2.9 | 10 |
| 806 | Multilingual Learning for Mild Cognitive Impairment Screening from a Clinical Speech Task. , 0, , . | | 0 |
| 807 | Spatio-Semantic Graphs From Picture Description: Applications to Detection of Cognitive Impairment. Frontiers in Neurology, 2021, 12, 795374. | 1.1 | 3 |
| 808 | Electrophysiological resting state brain network and episodic memory in healthy aging adults. NeuroImage, 2022, 253, 118926. | 2.1 | 4 |
| 809 | Gut microbiota in patients with Alzheimerâ€™s disease spectrum: a systematic review and meta-analysis. Aging, 2022, 14, 477-496. | 1.4 | 61 |
| 810 | Neuronal-Derived EV Biomarkers Track Cognitive Decline in Alzheimerâ€™s Disease. Cells, 2022, 11, 436. | 1.8 | 18 |
| 811 | Age-related differences in white matter microstructure measured by advanced diffusion MRI in healthy older adults at risk for Alzheimerâ€™s disease. Aging Brain, 2022, 2, 100030. | 0.7 | 10 |
| 812 | Delusion and Delirium in Neurodegenerative Disorders: An Overlooked Relationship?. Frontiers in Psychiatry, 2021, 12, 808724. | 1.3 | 4 |
| 814 | Alzheimer disease and neuroplasticity. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2022, 184, 473-479. | 1.0 | 12 |
| 815 | Multivariate Assessment of Lipoxidative Metabolites, Trace Biometals, and Antioxidant and Detoxifying Activities in the Cerebrospinal Fluid Define a Fingerprint of Preclinical Stages of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 86, 387-402. | 1.2 | 3 |

| # | ARTICLE | IF | CITATIONS |
|---|---|---|---|
| 816 | Proteomic analysis of human hippocampal subfields provides new insights into the pathogenesis of Alzheimer's disease and the role of glial cells. Brain Pathology, 2022, 32, e13047. | 2.1 | 14 |
| 817 | Genome-Wide association study of quantitative biomarkers identifies a novel locus for alzheimer's disease at 12p12.1. BMC Genomics, 2022, 23, 85. | 1.2 | 7 |
| 818 | Reactive astrogliosis: A friend or foe in the pathogenesis of Alzheimer's disease. Journal of Neurochemistry, 2023, 164, 309-324. | 2.1 | 43 |
| 819 | Functional insight into LOAD-associated microglial response genes. Open Biology, 2022, 12, 210280. | 1.5 | 5 |
| 820 | Episodic Memory Impairment Mediates the Loss of Awareness in Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2021, 13, 802501. | 1.7 | 7 |
| 821 | Using radiomics-based modelling to predict individual progression from mild cognitive impairment to Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2163-2173. | 3.3 | 20 |
| 823 | Neurobiological Highlights of Cognitive Impairment in Psychiatric Disorders. International Journal of Molecular Sciences, 2022, 23, 1217. | 1.8 | 26 |
| 824 | Methods to study the effect of solution variables on the conformational dynamics of intrinsically disordered proteins. , 2022, , 551-563. |  | 1 |
| 825 | A Natural History of Disease Framework for Improving the Prevention, Management, and Research on Post-viral Fatigue Syndrome and Other Forms of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Frontiers in Medicine, 2021, 8, 688159. | 1.2 | 6 |
| 827 | Functional connectivity density alterations in children with strabismus and amblyopia based on resting-state functional magnetic resonance imaging (fMRI). BMC Ophthalmology, 2022, 22, 49. | 0.6 | 3 |
| 828 | Multidimensional Dynamics of the Proteome in the Neurodegenerative and Aging Mammalian Brain. Molecular and Cellular Proteomics, 2022, 21, 100192. | 2.5 | 5 |
| 829 | Neuroprotective Effect of HIIT against GFAP Hypertrophy through Mitochondrial Dynamics in APP/PS1 Mice. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-14. | 1.9 | 3 |
| 830 | Alpha desynchronization during Stroop test unmasks cognitively healthy individuals with abnormal CSF Amyloid/Tau. Neurobiology of Aging, 2022, 112, 87-101. | 1.5 | 8 |
| 831 | Subtle postoperative cognitive disorder in preclinical Alzheimer's disease. Experimental Gerontology, 2022, 161, 111715. | 1.2 | 0 |
| 832 | Weighted Brain Network Analysis on Different Stages of Clinical Cognitive Decline. Bioengineering, 2022, 9, 62. | 1.6 | 5 |
| 833 | Structure of the drug treatment adherence in elderly patients with mild cognitive impairment and psychopathological symptoms. Kazan Medical Journal, 2022, 103, 44-53. | 0.1 | 0 |
| 834 | What have we learnt from past failures in Alzheimer's disease drug discovery?. Expert Opinion on Drug Discovery, 2022, 17, 309-323. | 2.5 | 9 |
| 835 | Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review. Alzheimer's Research and Therapy, 2022, 14, 31. | 3.0 | 25 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 836 | Associations Between Retinal Nerve Fiber Layer and Ganglion Cell Layer in Middle Age and Cognition From Childhood to Adulthood. JAMA Ophthalmology, 2022, 140, 262. | 1.4 | 15 |
| 837 | The potential utility of smell testing to screen for neurodegenerative disorders. Expert Review of Molecular Diagnostics, 2022, 22, 139-148. | 1.5 | 1 |
| 838 | Stratification of the Gut Microbiota Composition Landscape across the Alzheimer's Disease Continuum in a Turkish Cohort. MSystems, 2022, 7, e0000422. | 1.7 | 20 |
| 839 | Artificial Intelligence based Modern Approaches to Diagnose Alzheimer s. Indian Journal of Artifical Intelligence and Neural Networking, 2022, 2, 1-14. | 0.2 | 0 |
| 840 | Exploring dynamic functional connectivity alterations in the preclinical stage of Alzheimer's disease: an exploratory study from SILCODE. Journal of Neural Engineering, 2022, , . | 1.8 | 2 |
| 841 | Recent Advances in the Application Peptide and Peptoid in Diagnosis Biomarkers of Alzheimer's Disease in Blood. Frontiers in Molecular Neuroscience, 2021, 14, 778955. | 1.4 | 4 |
| 845 | Alzheimer's disease amyloid-β pathology in the lens of the eye. Experimental Eye Research, 2022, 221, 108974. | 1.2 | 5 |
| 846 | The Trajectory of Cerebrospinal Fluid Growth-Associated Protein 43 in the Alzheimer's Disease Continuum: A Longitudinal Study. Journal of Alzheimer's Disease, 2022, 85, 1441-1452. | 1.2 | 7 |
| 848 | BMNet: A New Region-Based Metric Learning Method for Early Alzheimer's Disease Identification With FDG-PET Images. Frontiers in Neuroscience, 2022, 16, 831533. | 1.4 | 9 |
| 849 | Therapeutic Efficacies of Berberine against Neurological Disorders: An Update of Pharmacological Effects and Mechanisms. Cells, 2022, 11, 796. | 1.8 | 13 |
| 850 | Current Concepts of Mixed Pathologies in Neurodegenerative Diseases. Canadian Journal of Neurological Sciences, 2023, 50, 329-345. | 0.3 | 22 |
| 851 | Causal Evidence for the Multiple Demand Network in Change Detection: Auditory Mismatch Magnetoencephalography across Focal Neurodegenerative Diseases. Journal of Neuroscience, 2022, 42, 3197-3215. | 1.7 | 14 |
| 852 | A Digital Screening System for Alzheimer Disease Based on a Neuropsychological Test and a Convolutional Neural Network: System Development and Validation. JMIR Medical Informatics, 2022, 10, e31106. | 1.3 | 9 |
| 853 | Fluid Biomarkers in Alzheimer's Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments. Diagnostics, 2022, 12, 796. | 1.3 | 4 |
| 854 | Higher Serum DHA and Slower Cognitive Decline in Patients with Alzheimer's Disease: Two-Year Follow-Up. Nutrients, 2022, 14, 1159. | 1.7 | 17 |
| 855 | Identification of cognitively impaired patients at risk for development of Alzheimer's disease dementia: an analysis of US Medicare claims data. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, , 1-14. | 0.7 | 1 |
| 856 | Potential Mechanisms Underlying Resistance to Dementia in Non-Demented Individuals with Alzheimer's Disease Neuropathology. Journal of Alzheimer's Disease, 2022, 87, 51-81. | 1.2 | 14 |
| 858 | Hyperphosphorylated Tau Relates to Improved Cognitive Performance and Reduced Hippocampal Excitability in the Young rTg4510 Mouse Model of Tauopathy. Journal of Alzheimer's Disease, 2022, , 1-15. | 1.2 | 4 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 859 | Personalized Management and Treatment of Alzheimer's Disease. Life, 2022, 12, 460. | 1.1 | 4 |
| 861 | Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes. Nature Reviews Neurology, 2022, 18, 323-332. | 4.9 | 29 |
| 862 | Hypoxic Preconditioning Averts Sporadic Alzheimer's Disease-Like Phenotype in Rats: A Focus on Mitochondria. Antioxidants and Redox Signaling, 2022, 37, 739-757. | 2.5 | 6 |
| 864 | Subjective Cognitive Decline Is More Accurate When Metamemory Is Better. Frontiers in Aging Neuroscience, 2022, 14, 787552. | 1.7 | 3 |
| 865 | Mitigating Effect of Estrogen in Alzheimer's Disease-Mimicking Cerebral Organoid. Frontiers in Neuroscience, 2022, 16, 816174. | 1.4 | 10 |
| 867 | Island Study Linking Aging and Neurodegenerative Disease (ISLAND) Targeting Dementia Risk Reduction: Protocol for a Prospective Web-Based Cohort Study. JMIR Research Protocols, 2022, 11, e34688. | 0.5 | 13 |
| 868 | Possibility for Prevention of Type 2 Diabetes Mellitus and Dementia Using Three Kinds of Brown Rice Blends after High-Pressure Treatment. Foods, 2022, 11, 818. | 1.9 | 6 |
| 869 | "I Know Hyena. Do you Know Hyena?"Challenges in Interpreter-Mediated Dementia Assessment, Focusing on the Role of the Interpreter. Journal of Cross-Cultural Gerontology, 2022, 37, 45-67. | 0.5 | 8 |
| 870 | Sex Differences in Demographic and Pharmacological Factors in Alzheimer Patients With Dementia and Cognitive Impairments. Frontiers in Behavioral Neuroscience, 2022, 16, 828782. | 1.0 | 4 |
| 871 | Diagnostic Accuracy of the Five-Word Test for Mild Cognitive Impairment Due to Alzheimer's Disease. Neurology International, 2022, 14, 357-367. | 1.3 | 2 |
| 872 | Dihydromyricetin improves social isolation-induced cognitive impairments and astrocytic changes in mice. Scientific Reports, 2022, 12, 5899. | 1.6 | 5 |
| 873 | A robust and interpretable machine learning approach using multimodal biological data to predict future pathological tau accumulation. Nature Communications, 2022, 13, 1887. | 5.8 | 16 |
| 874 | The Relationship Between Multimorbidity and Types of Chronic Diseases and Self-Rated Memory. Research on Aging, 2023, 45, 149-160. | 0.9 | 1 |
| 875 | Directional DBS of the Fornix in Alzheimer's Disease Achieves Long-Term Benefits: A Case Report. Frontiers in Aging Neuroscience, 2022, 14, 809972. | 1.7 | 3 |
| 876 | The identification of PSEN1 p.Tyr159Ser mutation in a non-canonic early-onset Alzheimer's disease family. Molecular and Cellular Neurosciences, 2022, 120, 103715. | 1.0 | 4 |
| 877 | Theta and gamma oscillatory dynamics in mouse models of Alzheimer's disease: A path to prospective therapeutic intervention. Neuroscience and Biobehavioral Reviews, 2022, 136, 104628. | 2.9 | 16 |
| 878 | Late combination shows that MEG adds to MRI in classifying MCI versus controls. NeuroImage, 2022, 252, 119054. | 2.1 | 12 |
| 879 | Relationship between Resting State Heart Rate Variability and Sleep Quality in Older Adults with Mild Cognitive Impairment. International Journal of Environmental Research and Public Health, 2021, 18, 13321. | 1.2 | 1 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 880 | Rest-Activity Pattern and Circadian Phase Alterations Across the Alzheimer's Disease Clinical Spectrum. Chronobiology in Medicine, 2021, 3, 137-141. | 0.2 | 1 |
| 881 | Alzheimer disease effects of different stages on intestinal flora. Medicine (United States), 2021, 100, e28462. | 0.4 | 1 |
| 882 | Limited Longitudinal Change in Self-reported Spatial Navigation Ability in Preclinical Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2022, 36, 15-21. | 0.6 | 3 |
| 883 | Patterns of lifestyle behaviours from mid- through later-life in relation to exceptional episodic memory performance in older women: the Nurses' Health Study. Age and Ageing, 2022, 51, . | 0.7 | 2 |
| 884 | Crystal Ball Health Policies: A Case Against Preventive Testing For Alzheimer's Disease. Frontiers in Aging Neuroscience, 2022, 14, 842629. | 1.7 | 1 |
| 885 | Characterization of Altered Molecular Pathways in the Entorhinal Cortex of Alzheimer's Disease Patients and In Silico Prediction of Potential Repurposable Drugs. Genes, 2022, 13, 703. | 1.0 | 3 |
| 886 | Stereotaxic-assisted gene therapy in Alzheimer's and Parkinson's diseases: therapeutic potentials and clinical frontiers. Expert Review of Neurotherapeutics, 2022, 22, 319-335. | 1.4 | 1 |
| 887 | Cross-Cultural Longitudinal Study on Cognitive Decline (CLoCODE) for Subjective Cognitive Decline in China and Germany: A Protocol for Study Design. Journal of Alzheimer's Disease, 2022, , 1-15. | 1.2 | 6 |
| 908 | A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer's Disease. journal of prevention of Alzheimer's disease, The, 0, , . | 1.5 | 2 |
| 909 | Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study. Biomedicines, 2022, 10, 1045. | 1.4 | 1 |
| 910 | How to use neuroimaging biomarkers in the diagnosis framework of neurodegenerative diseases?. Revue Neurologique, 2022, 178, 490-497. | 0.6 | 2 |
| 911 | Functional Imaging for Neurodegenerative Diseases. Presse Medicale, 2022, 51, 104121. | 0.8 | 3 |
| 912 | Using Deep Learning Radiomics to Distinguish Cognitively Normal Adults at Risk of Alzheimer's Disease From Normal Control: An Exploratory Study Based on Structural MRI. Frontiers in Medicine, 2022, 9, 894726. | 1.2 | 6 |
| 913 | Ovocystatin Induced Changes in Expression of Alzheimer's Disease Relevant Proteins in APP/PS1 Transgenic Mice. Journal of Clinical Medicine, 2022, 11, 2372. | 1.0 | 2 |
| 914 | Practice Effects in Mild Cognitive Impairment Increase Reversion Rates and Delay Detection of New Impairments. Frontiers in Aging Neuroscience, 2022, 14, 847315. | 1.7 | 3 |
| 915 | The Relationship Between Muscle Strength and Cognitive Performance Across Alzheimer's Disease Clinical Continuum. Frontiers in Neurology, 2022, 13, . | 1.1 | 12 |
| 916 | How can we define the presymptomatic C9orf72 disease in 2022? An overview on the current definitions of preclinical and prodromal phases. Revue Neurologique, 2022, 178, 426-436. | 0.6 | 2 |
| 917 | Gut Microbiota and Subjective Memory Complaints in Older Women. Journal of Alzheimer's Disease, 2022, , 1-12. | 1.2 | 3 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 918 | Assessing the Clinical Meaningfulness of the Alzheimer's Disease Composite Score (ADCOMS) Tool. Neurology and Therapy, 2022, , . | 1.4 | 1 |
| 919 | Understanding brain function in vascular cognitive impairment and dementia with EEG and MEG: A systematic review. NeuroImage: Clinical, 2022, 35, 103040. | 1.4 | 10 |
| 920 | Impaired Affordance Perception as the Basis of Tool Use Deficiency in Alzheimer's Disease. Healthcare (Switzerland), 2022, 10, 839. | 1.0 | 2 |
| 921 | Neuronal ER-Signalosome Proteins as Early Biomarkers in Prodromal Alzheimer's Disease Independent of Amyloid-Î² Production and Tau Phosphorylation. Frontiers in Molecular Neuroscience, 2022, 15, . | 1.4 | 6 |
| 922 | The cross-sectional and longitudinal relationship of diabetic retinopathy to cognitive impairment: a systematic review and meta-analysis. Eye, 2023, 37, 220-227. | 1.1 | 3 |
| 923 | Treatment effects on event-related EEG potentials and oscillations in Alzheimer's disease. International Journal of Psychophysiology, 2022, 177, 179-201. | 0.5 | 7 |
| 924 | Prefrontal Activation During Effortful Processing Differentiates Memory Abilities in Adults with Memory Complaints. Journal of Alzheimer's Disease, 2022, 88, 301-310. | 1.2 | 1 |
| 925 | The Current Landscape of Prevention Trials in Dementia. Neurotherapeutics, 2022, 19, 228-247. | 2.1 | 10 |
| 926 | A multi-site, multi-participant magnetoencephalography resting-state dataset to study dementia: The BioFIND dataset. NeuroImage, 2022, 258, 119344. | 2.1 | 7 |
| 927 | Integrative analysis of summary data from GWAS and eQTL studies implicates genes differentially expressed in Alzheimer's disease. BMC Genomics, 2022, 23, . | 1.2 | 6 |
| 928 | Effects of Aerobic Training on Brain Plasticity in Patients with Mild Cognitive Impairment: A Systematic Review of Randomized Controlled Trials. Brain Sciences, 2022, 12, 732. | 1.1 | 6 |
| 929 | Global estimates on the number of persons across the Alzheimer's disease continuum. Alzheimer's and Dementia, 2023, 19, 658-670. | 0.4 | 146 |
| 930 | Genetic Variation in Targets of Antidiabetic Drugs and Alzheimer Disease Risk. Neurology, 2022, 99, . | 1.5 | 18 |
| 932 | Potential for Ketotherapies as Amyloid-Regulating Treatment in Individuals at Risk for Alzheimer's Disease. Frontiers in Neuroscience, 0, 16, . | 1.4 | 7 |
| 933 | Incremental diagnostic value of 18F-Fluetemetamol PET in differential diagnoses of Alzheimer's Disease-related neurodegenerative diseases from an unselected memory clinic cohort. Scientific Reports, 2022, 12, . | 1.6 | 3 |
| 934 | Classification of early-MCI patients from healthy controls using evolutionary optimization of graph measures of resting-state fMRI, for the Alzheimer's disease neuroimaging initiative. PLoS ONE, 2022, 17, e0267608. | 1.1 | 11 |
| 935 | Natural Pattern of Cognitive Aging. Journal of Alzheimer's Disease, 2022, 88, 1147-1155. | 1.2 | 3 |
| 936 | Cortical excitability and plasticity in Alzheimer's disease and mild cognitive impairment: A systematic review and meta-analysis of transcranial magnetic stimulation studies. Ageing Research Reviews, 2022, 79, 101660. | 5.0 | 15 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 937 | A combination model of AD biomarkers revealed by machine learning precisely predicts Alzheimer's dementia: China Aging and Neurodegenerative Initiative (CANDI) study. Alzheimer's and Dementia, 2023, 19, 749-760. | 0.4 | 20 |
| 938 | Modified cued recall test in the French population with Down syndrome: A retrospective medical records analysis. Journal of Intellectual Disability Research, 2022, 66, 690-703. | 1.2 | 2 |
| 939 | Predictive Scale for Amyloid PET Positivity Based on Clinical and MRI Variables in Patients with Amnestic Mild Cognitive Impairment. Journal of Clinical Medicine, 2022, 11, 3433. | 1.0 | 3 |
| 940 | Phosphorylated Tau 181 Serum Levels Predict Alzheimer's Disease in the Preclinical Stage. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 6 |
| 941 | Staging of Alzheimer's disease: past, present, and future perspectives. Trends in Molecular Medicine, 2022, 28, 726-741. | 3.5 | 36 |
| 942 | Quantitative electroencephalography changes in patients with mild cognitive impairment after choline alphoscerate administration. Journal of Clinical Neuroscience, 2022, 102, 42-48. | 0.8 | 3 |
| 943 | Overview of therapeutic targets in management of dementia. Biomedicine and Pharmacotherapy, 2022, 152, 113168. | 2.5 | 15 |
| 945 | A Dichotomous Role for FABP7 in Sleep and Alzheimer's Disease Pathogenesis: A Hypothesis. Frontiers in Neuroscience, 0, 16, . | 1.4 | 6 |
| 946 | Amylin and Secretases in the Pathology and Treatment of Alzheimer's Disease. Biomolecules, 2022, 12, 996. | 1.8 | 5 |
| 947 | Subjective Cognitive Decline: Is a Resilient Personality Protective Against Progression to Objective Cognitive Impairment? Findings from Two Community-Based Cohort Studies. Journal of Alzheimer's Disease, 2022, 89, 87-105. | 1.2 | 4 |
| 948 | The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders. Translational Neurodegeneration, 2022, 11, . | 3.6 | 15 |
| 949 | Risk Factors for Dementia in Patients With Incident Rheumatoid Arthritis: A Population-Based Cohort Study. Journal of Rheumatology, 2023, 50, 48-55. | 1.0 | 8 |
| 950 | Self- and Partner-Reported Subjective Memory Complaints: Association with Objective Cognitive Impairment and Risk of Decline. Journal of Alzheimer's Disease Reports, 2022, 6, 411-430. | 1.2 | 4 |
| 951 | Application of Diffusion Tensor Imaging Based on Automatic Fiber Quantification in Alzheimer's Disease. Current Alzheimer Research, 2022, 19, 469-478. | 0.7 | 2 |
| 952 | Kallikrein 8: A key sheddase to strengthen and stabilize neural plasticity. Neuroscience and Biobehavioral Reviews, 2022, 140, 104774. | 2.9 | 2 |
| 953 | Potential Diagnostic Applications of Multi-Delay Arterial Spin Labeling in Early Alzheimer's Disease: The Chinese Imaging, Biomarkers, and Lifestyle Study. Frontiers in Neuroscience, 0, 16, . | 1.4 | 3 |
| 954 | Prospective biomarkers of Alzheimer's disease: A systematic review and meta-analysis. Ageing Research Reviews, 2022, 81, 101699. | 5.0 | 17 |
| 955 | Brain transcriptomic profiling reveals common alterations across neurodegenerative and psychiatric disorders. Computational and Structural Biotechnology Journal, 2022, 20, 4549-4561. | 1.9 | 7 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 956 | The Clinical Use of Alzheimerâ€™s Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimerâ€™s Disease Consortium Survey. Journal of Alzheimer's Disease, 2022, 89, 535-551. | 1.2 | 7 |
| 957 | A robust framework to investigate the reliability and stability of explainable artificial intelligence markers of Mild Cognitive Impairment and Alzheimerâ€™s Disease. Brain Informatics, 2022, 9, . | 1.8 | 15 |
| 958 | Neuronal cell death mechanisms in Alzheimerâ€™s disease: An insight. Frontiers in Molecular Neuroscience, 0, 15, . | 1.4 | 36 |
| 959 | Biomarkers for the Diagnosis of Alzheimerâ€™s Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria. International Journal of Molecular Sciences, 2022, 23, 8598. | 1.8 | 9 |
| 960 | Extracellular vesicles and Alzheimerâ€™s disease in the novel era of Precision Medicine: implications for disease progression, diagnosis and treatment. Experimental Neurology, 2022, 358, 114183. | 2.0 | 10 |
| 961 | Amyloid-Î² levels and cognitive trajectories in non-demented pTau181-positive subjects without amyloidopathy. Brain, 2022, 145, 4032-4041. | 3.7 | 12 |
| 962 | Role of estrogen receptors in health and disease. Frontiers in Endocrinology, 0, 13, . | 1.5 | 42 |
| 963 | Artificial Intelligence Models in the Diagnosis of Adult-Onset Dementia Disorders: A Review. Bioengineering, 2022, 9, 370. | 1.6 | 15 |
| 964 | Impaired sharp-wave ripple coordination between the medial entorhinal cortex and hippocampal CA1 of knock-in model of Alzheimerâ€™s disease. Frontiers in Systems Neuroscience, 0, 16, . | 1.2 | 5 |
| 965 | Sex specific EEG signatures associated with cerebrospinal fluid biomarkers in mild cognitive impairment. Clinical Neurophysiology, 2022, 142, 190-198. | 0.7 | 2 |
| 966 | Improving Our Understanding of Driving Changes in Preclinical and Early Symptomatic Alzheimerâ€™s Disease: The Role of Naturalistic Driving Studies. Journal of Alzheimer's Disease Reports, 2022, 6, 521-528. | 1.2 | 1 |
| 968 | Designing the next-generation clinical care pathway for Alzheimerâ€™s disease. Nature Aging, 2022, 2, 692-703. | 5.3 | 44 |
| 969 | Can we really â€˜readâ€™ art to see the changing brain? A review and empirical assessment of clinical case reports and published artworks for systematic evidence of quality and style changes linked to damage or neurodegenerative disease. Physics of Life Reviews, 2022, 43, 32-95. | 1.5 | 17 |
| 971 | Association of Enlarged Perivascular Spaces With Amyloid Burden and Cognitive Decline in Alzheimer Disease Continuum. Neurology, 2022, 99, . | 1.5 | 14 |
| 972 | Multimodal magnetic resonance imaging reveals distinct sensitivity of hippocampal subfields in asymptomatic stage of Alzheimerâ€™s disease. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 1 |
| 973 | Association between serum total bilirubin and Alzheimer's disease: A bidirectional Mendelian randomization study. Archives of Gerontology and Geriatrics, 2022, 103, 104786. | 1.4 | 2 |
| 974 | Individualized diagnosis of preclinical Alzheimerâ€™s Disease using deep neural networks. Expert Systems With Applications, 2022, 210, 118511. | 4.4 | 4 |
| 975 | Proteomics of serum exosomes identified fibulin-1 as a novel biomarker for mild cognitive impairment. Neural Regeneration Research, 2023, 18, 587. | 1.6 | 5 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 976 | Theta Band-Power Shapes Amyloid-Driven Longitudinal EEG Changes in Elderly Subjective Memory Complainers At-Risk for Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 90, 69-84. | 1.2 | 6 |
| 977 | The Molecular Effects of Environmental Enrichment on Alzheimer's Disease. Molecular Neurobiology, 2022, 59, 7095-7118. | 1.9 | 15 |
| 978 | Association between frequency of going out and mild cognitive impairment in community‐dwelling older adults: a pilot study in frailty prevention groups. Psychogeriatrics, 0, , . | 0.6 | 0 |
| 979 | Research trends and hotspots of exercise for Alzheimer's disease: A bibliometric analysis. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 8 |
| 980 | Effects of oral health intervention strategies on cognition and microbiota alterations in patients with mild Alzheimer's disease: A randomized controlled trial. Geriatric Nursing, 2022, 48, 103-110. | 0.9 | 5 |
| 981 | How molecular imaging studies can disentangle disease mechanisms in age-related neurodegenerative disorders. , 2023, , 455-492. | | 0 |
| 982 | Abnormal cerebrospinal fluid levels of amyloid and tau are associated with cognitive decline over time in cognitively normal older adults: A monozygotic twin study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, . | 1.8 | 5 |
| 983 | Expression of Regional Amyloid Deposition in Centiloid Scale and Used for Quantitative Analysis in Alzheimer's Disease-A Multi-Site Study. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 984 | Pharmacogenomics of Alzheimer's Disease: Novel Strategies for Drug Utilization and Development. Methods in Molecular Biology, 2022, , 275-387. | 0.4 | 4 |
| 986 | Preliminary study on the impact of EEG density on TMS-EEG classification in Alzheimer's disease. , 2022, , . | | 2 |
| 987 | Plasma biomarkers and their correlation in adult children of parents with Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 1 |
| 989 | Understanding the Relationship Between Age-Related Hearing Loss and Alzheimer's Disease: A Narrative Review. Journal of Alzheimer's Disease Reports, 2022, 6, 539-556. | 1.2 | 5 |
| 990 | Response to the letter titled "The conundrum of the AD continuum" Alzheimer's and Dementia, 0, , . | 0.4 | 0 |
| 991 | Safety and efficacy of plasma transfusion from exercise-trained donors in patients with early Alzheimer's disease: protocol for the ExPlas study. BMJ Open, 2022, 12, e056964. | 0.8 | 2 |
| 992 | Regional Precuneus Cortical Hyperexcitability in Alzheimer's Disease Patients. Annals of Neurology, 2023, 93, 371-383. | 2.8 | 19 |
| 993 | Longitudinal change in serial position scores in older adults with entorhinal and hippocampal neuropathologies. Journal of the International Neuropsychological Society, 2023, 29, 561-571. | 1.2 | 3 |
| 994 | Prediction of Alzheimer's Disease Using Patterns of Methylation Levels in Key Immunologic-Related Genes. Journal of Alzheimer's Disease, 2022, 90, 783-794. | 1.2 | 1 |
| 995 | Early detection of Alzheimer's disease using neuropsychological tests: a predict‐diagnose approach using neural networks. Brain Informatics, 2022, 9, . | 1.8 | 5 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 996 | Subjective cognitive decline and anxious/depressive symptoms during the COVID-19 pandemic: what is the role of stress perception, stress resilience, and Î²-amyloid?. Alzheimer's Research and Therapy, 2022, 14, . | 3.0 | 3 |
| 998 | How can secondary dementia prevention trials of Alzheimer's disease be clinically meaningful?. Alzheimer's and Dementia, 2023, 19, 1073-1085. | 0.4 | 1 |
| 999 | Memory markers in the continuum of the Alzheimerâ€™s clinical syndrome. Alzheimer's Research and Therapy, 2022, 14, . | 3.0 | 6 |
| 1001 | FSH-blocking therapeutic for osteoporosis. ELife, 0, 11, . | 2.8 | 9 |
| 1002 | The conundrum of the AD continuum. Alzheimer's and Dementia, 2023, 19, 371-372. | 0.4 | 1 |
| 1004 | Cognitive Functioning of Unaffected First-degree Relatives of Individuals With Late-onset Alzheimer's Disease: A Systematic Literature Review and Meta-analysis. Neuropsychology Review, 2023, 33, 659-674. | 2.5 | 4 |
| 1005 | The Asparaginyl Endopeptidase Legumain: An Emerging Therapeutic Target and Potential Biomarker for Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 10223. | 1.8 | 10 |
| 1006 | Case Report: A neurolinguistic and neuroimaging study on a Chinese follow-up case with logopenic-variant of primary progressive aphasia. Frontiers in Neurology, 0, 13, . | 1.1 | 0 |
| 1007 | The impact of conventional versus robust norming on cognitive characterization and clinical classification of <scp>MCI</scp> and dementia. Journal of Neuropsychology, 0, , . | 0.6 | 2 |
| 1008 | Preclinical Alzheimer Disease and the Electronic Health Record. Neurology, 2022, 99, 987-994. | 1.5 | 4 |
| 1009 | Systematic and Bibliometric Analysis of Magnetite Nanoparticles and Their Applications in (Biomedical) Research. Global Challenges, 2023, 7, . | 1.8 | 3 |
| 1010 | Higher amyloid correlates to greater loneliness during the COVID-19 pandemic. F1000Research, 0, 11, 1134. | 0.8 | 0 |
| 1011 | Alzheimer's disease: genetic and modifiable lifestyle influences. , 2023, , 68-76. | | 0 |
| 1012 | US Adultsâ€™ Likelihood to Participate in Dementia Prevention Drug Trials: Results from the National Poll on Healthy Aging. journal of prevention of Alzheimer's disease, The, 0, , . | 1.5 | 1 |
| 1013 | Cholinergic white matter pathways along the Alzheimer's disease continuum. Brain, 2023, 146, 2075-2088. | 3.7 | 12 |
| 1014 | Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimerâ€™s disease. Clinical Chemistry and Laboratory Medicine, 2023, 61, 234-244. | 1.4 | 2 |
| 1015 | Spatio-temporal metabolic rewiring in the brain of TgF344-AD rat model of Alzheimerâ€™s disease. Scientific Reports, 2022, 12, . | 1.6 | 0 |
| 1016 | Hypothesis review: Alzheimer's overture guidelines. Brain Pathology, 2023, 33, . | 2.1 | 18 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1018 | A case report and literature review of cognitive malingering and psychopathology. Frontiers in Psychiatry, 0, 13, . | 1.3 | 0 |
| 1020 | Preclinical Alzheimerâ€™s dementia: a useful concept or another dead end?. European Journal of Ageing, 2022, 19, 997-1004. | 1.2 | 5 |
| 1021 | Dietary Selenomethionine Reduce Mercury Tissue Levels and Modulate Methylmercury Induced Proteomic and Transcriptomic Alterations in Hippocampi of Adolescent BALB/c Mice. International Journal of Molecular Sciences, 2022, 23, 12242. | 1.8 | 3 |
| 1022 | Meta analysis of aerobic exercise improving intelligence and cognitive function in patients with Alzheimerâ€™s disease. Medicine (United States), 2022, 101, e31177. | 0.4 | 4 |
| 1023 | Imaging Biomarkers for Central Nervous System Drug Development and Future Clinical Utility: Lessons from Neurodegenerative Disorders. Journal of Nuclear Medicine, 2023, 64, 12-19. | 2.8 | 5 |
| 1024 | Cognitive Impairment in Older Adults. Psychiatric Clinics of North America, 2022, 45, 639-661. | 0.7 | 12 |
| 1025 | Guanidine-based Î² amyloid precursor protein cleavage enzyme 1 (BACE-1) inhibitors for the Alzheimer's disease (AD): A review. Bioorganic and Medicinal Chemistry, 2022, 74, 117047. | 1.4 | 11 |
| 1026 | Modelling the Pan-European Economic Burden of Alzheimerâ€™s Disease. JAR Life, 0, , . | 0.0 | 0 |
| 1027 | Potential role of dietary nitrate in relation to cardiovascular and cerebrovascular health, cognition, cognitive decline and dementia: a review. Food and Function, 2022, 13, 12572-12589. | 2.1 | 6 |
| 1028 | On Disharmony in Batch Normalization and Dropout Methods for Early Categorization of Alzheimerâ€™s Disease. Sustainability, 2022, 14, 14695. | 1.6 | 9 |
| 1029 | Alzheimerâ€™s Disease: Treatment Strategies and Their Limitations. International Journal of Molecular Sciences, 2022, 23, 13954. | 1.8 | 66 |
| 1030 | A distribution-free smoothed combination method to improve discrimination accuracy in multi-category classification. Statistical Methods in Medical Research, 0, , 09622802221377. | 0.7 | 1 |
| 1031 | Electroacupuncture ameliorates cerebrovascular impairment in Alzheimer's disease mice via melatonin signaling. CNS Neuroscience and Therapeutics, 2023, 29, 917-931. | 1.9 | 3 |
| 1032 | Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2022, 14, . | 3.0 | 16 |
| 1033 | Measurement of Prevalent Versus Incident Dementia Cases in Epidemiologic Studies. American Journal of Epidemiology, 0, , . | 1.6 | 1 |
| 1035 | Interdisciplinary Approaches to Deal with Alzheimerâ€™s Diseaseâ€"From Bench to Bedside: What Feasible Options Do Already Exist Today?. Biomedicines, 2022, 10, 2922. | 1.4 | 1 |
| 1036 | Therapeutic Potential of Targeting Mitochondria for Alzheimerâ€™s Disease Treatment. Journal of Clinical Medicine, 2022, 11, 6742. | 1.0 | 5 |
| 1037 | Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 2084-2094. | 0.4 | 2 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1038 | Fear of Dementia and the Obligation to Provide Aggregate Research Results to Study Participants. Cambridge Quarterly of Healthcare Ethics, 2022, 31, 498-505. | 0.5 | 2 |
| 1039 | Toward the Identification of Neurophysiological Biomarkers for Alzheimer's Disease in Down Syndrome: A Potential Role for Cross-Frequency Phase-Amplitude Coupling Analysis. , 2022, . | | 2 |
| 1040 | Advanced theragnostics for the central nervous system (CNS) and neurological disorders using functional inorganic nanomaterials. Advanced Drug Delivery Reviews, 2023, 192, 114636. | 6.6 | 7 |
| 1041 | Combined use of dasatinib and quercetin alleviates overtraining-induced deficits in learning and memory through eliminating senescent cells and reducing apoptotic cells in rat hippocampus. Behavioural Brain Research, 2023, 440, 114260. | 1.2 | 3 |
| 1042 | Thiazolidin-4-one prevents against memory deficits, increase in phosphorylated tau protein, oxidative damage and cholinergic dysfunction in Alzheimer disease model: Comparison with donepezil drug. Brain Research Bulletin, 2023, 193, 1-10. | 1.4 | 4 |
| 1043 | Cerebrospinal fluid levels of fatty acid–binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, . | 1.2 | 3 |
| 1044 | The CircRNAs for Diagnostic, Prognostic, and Therapy in Alzheimer's Disease. Advances in Bioscience and Biotechnology (Print), 2022, 13, 507-526. | 0.3 | 0 |
| 1045 | Toward the optimized assessment of clinical outcomes in studies of novel treatments for Alzheimer's disease. Expert Review of Neurotherapeutics, 2022, 22, 863-873. | 1.4 | 1 |
| 1046 | Systematic evaluation of urinary formic acid as a new potential biomarker for Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 9 |
| 1047 | A Machine Learning Approach for Early Diagnosis of Cognitive Impairment Using Population-Based Data. Journal of Alzheimer's Disease, 2023, 91, 449-461. | 1.2 | 7 |
| 1048 | Gut microbiome alterations in preclinical Alzheimer's disease. PLoS ONE, 2022, 17, e0278276. | 1.1 | 12 |
| 1049 | Promoting Endogenous Neurogenesis as a Treatment for Alzheimer's Disease. Molecular Neurobiology, 2023, 60, 1353-1368. | 1.9 | 1 |
| 1050 | Connectivity between default mode and frontoparietal networks mediates the association between global amyloid-$\beta$ and episodic memory. Human Brain Mapping, 2023, 44, 1147-1157. | 1.9 | 4 |
| 1052 | Journeying to Ixtlan: Ethics of Psychedelic Medicine and Research for Alzheimer's Disease and Related Dementias. AJOB Neuroscience, 2023, 14, 107-123. | 0.6 | 29 |
| 1053 | Amyloid-$\beta$ and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer's disease polygenic risk score. BMC Neurology, 2022, 22, . | 0.8 | 1 |
| 1054 | Differences in resting state functional connectivity underlie visuomotor performance declines in older adults with a genetic risk (APOE $\epsilon$4) for Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 0 |
| 1055 | PICALM rs3851179 Variants Modulate Left Postcentral Cortex Thickness, CSF Amyloid $\beta$42, and Phosphorylated Tau in the Elderly. Brain Sciences, 2022, 12, 1681. | 1.1 | 2 |
| 1056 | The effect of a digital health coaching and health education protocol on cognition in adults at-risk for Alzheimer's. GeroScience, 2023, 45, 1147-1159. | 2.1 | 2 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1057 | Sexually Dimorphic Association of Circulating Plasminogen Activator Inhibitor-1 Levels and Body Mass Index with Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Pathology in Preclinical Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, , 1-11. | 1.2 | 1 |
| 1058 | Mayoâ€PACC: A parsimonious preclinical Alzheimer's disease cognitive composite comprised of publicâ€domain measures to facilitate clinical translation. Alzheimer's and Dementia, 2023, 19, 2575-2584. | 0.4 | 6 |
| 1059 | Entorhinal cortex dysfunction in Alzheimer's disease. Trends in Neurosciences, 2023, 46, 124-136. | 4.2 | 34 |
| 1060 | Pharmacological Inventions for Alzheimer Treatment in the United States of America: A Revision Patent from 2010 â€" 2020. journal of prevention of Alzheimer's disease, The, 0, , . | 1.5 | 1 |
| 1061 | Integration of amyloid-Î² oligomerization tendency as a plasma biomarker in Alzheimer's disease diagnosis. Frontiers in Neurology, 0, 13, . | 1.1 | 1 |
| 1062 | The Neuroprotective Effects and Therapeutic Potential of the Chalcone Cardamonin for Alzheimerâ€™s Disease. Brain Sciences, 2023, 13, 145. | 1.1 | 12 |
| 1063 | Visuoconstructional Abilities of Patients With Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimerâ€™s Disease. Journal of Geriatric Psychiatry and Neurology, 0, , 089198872211355. | 1.2 | 0 |
| 1064 | Differences in structural MRI and diffusion tensor imaging underlie visuomotor performance declines in older adults with an increased risk for Alzheimerâ€™s disease. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 3 |
| 1065 | Rapid progress in neuroimaging technologies fuels central nervous system translational medicine. Drug Discovery Today, 2023, 28, 103485. | 3.2 | 4 |
| 1066 | Rationale for a Multi-Factorial Approach for the Reversal of Cognitive Decline in Alzheimerâ€™s Disease and MCI: A Review. International Journal of Molecular Sciences, 2023, 24, 1659. | 1.8 | 16 |
| 1067 | Lesion-induced sprouting promotes neurophysiological integration of septal and entorhinal inputs to granule cells in the dentate gyrus of rats. Neurobiology of Learning and Memory, 2023, 198, 107723. | 1.0 | 0 |
| 1068 | Multi-Component Interventions in Older Adults Having Subjective Cognitive Decline (SCD)â€"A Review Article. Geriatrics (Switzerland), 2023, 8, 4. | 0.6 | 2 |
| 1069 | Pathogenesis of Dementia. International Journal of Molecular Sciences, 2023, 24, 543. | 1.8 | 17 |
| 1070 | An NIR-Driven Upconversion/C$_3$N$_4$/CoP Photocatalyst for Efficient Hydrogen Production by Inhibiting Electronâ€"Hole Pair Recombination for Alzheimerâ€™s Disease Therapy. ACS Nano, 2023, 17, 2222-2234. | 7.3 | 13 |
| 1071 | miRNAs and Alzheimerâ€™s Disease: Exploring the Role of Inflammation and Vitamin E in an Old-Age Population. Nutrients, 2023, 15, 634. | 1.7 | 3 |
| 1072 | Challenges and Opportunities of Metal Chelation Therapy in Trace Metals Overload-Induced Alzheimerâ€™s Disease. Neurotoxicity Research, 2023, 41, 270-287. | 1.3 | 10 |
| 1073 | Altered dynamics of glymphatic flow in a mature-onset Tet-off APP mouse model of amyloidosis. Alzheimer's Research and Therapy, 2023, 15, . | 3.0 | 3 |
| 1074 | Daily Energy Intake Distribution and Cognitive Performance in Non-Demented Individuals. Nutrients, 2023, 15, 673. | 1.7 | 1 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 1075 | Molecular Mechanisms of Neuroinflammation in Aging and Alzheimer's Disease Progression. International Journal of Molecular Sciences, 2023, 24, 1869. | 1.8 | 25 |
| 1076 | CELLULAR STRESS RESPONSE (HORMESIS) IN RESPONSE TO BIOACTIVE NUTRACEUTICALS WITH RELEVANCE TO ALZHEIMER DISEASE. Antioxidants and Redox Signaling, 0, , . | 2.5 | 1 |
| 1077 | Bayesian Simultaneous Partial Envelope Model with Application to an Imaging Genetics Analysis. , 2023, , 1-33. | | 1 |
| 1078 | Executive function abilities in cognitively healthy young and older adults—A cross-sectional study. Frontiers in Aging Neuroscience, 0, 15, . | 1.7 | 4 |
| 1079 | Cognitive and behavioral abnormalities in individuals with Alzheimer's disease, mild cognitive impairment, and subjective memory complaints. Current Psychology, 2024, 43, 800-810. | 1.7 | 4 |
| 1080 | Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment. Journal of Nanobiotechnology, 2023, 21, . | 4.2 | 2 |
| 1081 | Structural polymorphism and cytotoxicity of brain-derived $\beta$-amyloid extracts. Protein Science, 2023, 32, . | 3.1 | 4 |
| 1082 | Alzheimer's disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs. Biochemical Pharmacology, 2023, 211, 115522. | 2.0 | 15 |
| 1083 | Aggregation-induced emission: An illuminator in the brain. Coordination Chemistry Reviews, 2023, 482, 215070. | 9.5 | 6 |
| 1084 | Structural Proteomic Profiling of Cerebrospinal Fluids to Reveal Novel Conformational Biomarkers for Alzheimer's Disease. Journal of the American Society for Mass Spectrometry, 2023, 34, 459-471. | 1.2 | 0 |
| 1085 | Modern Methods of Diagnostics and Treatment of Neurodegenerative Diseases and Depression. Diagnostics, 2023, 13, 573. | 1.3 | 9 |
| 1086 | An attention-based deep learning approach for the classification of subjective cognitive decline and mild cognitive impairment using resting-state EEG. Journal of Neural Engineering, 2023, 20, 016048. | 1.8 | 13 |
| 1087 | Revisiting the intersection of microglial activation and neuroinflammation in Alzheimer's disease from the perspective of ferroptosis. Chemico-Biological Interactions, 2023, 375, 110387. | 1.7 | 12 |
| 1088 | Brain perfusion, cognition, and plasma Alzheimer's biomarkers in moyamoya disease. Alzheimer's and Dementia, 2023, 19, 3316-3326. | 0.4 | 2 |
| 1089 | The Quest for Neurodegenerative Disease Treatment—Focusing on Alzheimer's Disease Personalised Diets. Current Issues in Molecular Biology, 2023, 45, 1519-1535. | 1.0 | 2 |
| 1090 | Multifactorial glial responses and their contributions to Alzheimer's disease continuum. Clinical and Experimental Neuroimmunology, 2023, 14, 82-91. | 0.5 | 1 |
| 1091 | Alzheimer's Disease: A Brief History of Immunotherapies Targeting Amyloid $\beta$. International Journal of Molecular Sciences, 2023, 24, 3895. | 1.8 | 18 |
| 1092 | Biomarkers: Role and Scope in Neurological Disorders. Neurochemical Research, 2023, 48, 2029-2058. | 1.6 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1093 | Neuropathology‑based <i>APOE</i> genetic risk score better quantifies Alzheimer's risk. Alzheimer's and Dementia, 2023, 19, 3406-3416. | 0.4 | 2 |
| 1094 | Effects of risk factors on longitudinal changes in brain structure and function in the progression of AD. Alzheimer's and Dementia, 2023, 19, 2666-2676. | 0.4 | 1 |
| 1095 | Obesity impacts the expression of Alzheimer's disease–related genes: The Framingham Heart Study. Alzheimer's and Dementia, 2023, 19, 3496-3505. | 0.4 | 3 |
| 1096 | PASSED: Brain atrophy in non-demented individuals in a long-term longitudinal study from two independent cohorts. Frontiers in Aging Neuroscience, 0, 15, . | 1.7 | 1 |
| 1098 | Single‑cell sequencing of entorhinal cortex reveals widespread disruption of neuropeptide networks in Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 3575-3592. | 0.4 | 1 |
| 1099 | Through the eyes into the brain, using artificial intelligence. Annals of the Academy of Medicine, Singapore, 2023, 52, 88-95. | 0.2 | 2 |
| 1100 | The use of virtual reality in screening for preclinical Alzheimer's disease: A scoping review protocol. PLoS ONE, 2023, 18, e0282436. | 1.1 | 0 |
| 1101 | Extracellular Vesicles, Cell-Penetrating Peptides and miRNAs as Future Novel Therapeutic Interventions for Parkinson's and Alzheimer's Disease. Biomedicines, 2023, 11, 728. | 1.4 | 6 |
| 1103 | Cognitive and Neuropathophysiological Outcomes of Gamma-tACS in Dementia: A Systematic Review. Neuropsychology Review, 2024, 34, 338-361. | 2.5 | 6 |
| 1104 | Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials. Neurology, 2023, 101, 38-45. | 1.5 | 5 |
| 1105 | Assessing the Role of Past Depression in Patients with Mild Cognitive Impairment, with and without Biomarkers for Alzheimer's Disease. Journal of Alzheimer's Disease, 2023, 92, 1219-1227. | 1.2 | 0 |
| 1106 | Exercise suppresses neuroinflammation for alleviating Alzheimer's disease. Journal of Neuroinflammation, 2023, 20, . | 3.1 | 19 |
| 1108 | Revealing the correlations between brain cortical characteristics and susceptibility genes for Alzheimer disease: a cross-sectional study. Quantitative Imaging in Medicine and Surgery, 2023, 13, 2451-2465. | 1.1 | 0 |
| 1109 | Longitudinal Modeling of Age-Dependent Latent Traits with Generalized Additive Latent and Mixed Models. Psychometrika, 0, , . | 1.2 | 0 |
| 1110 | Association of retinal optical coherence tomography metrics and polygenic risk scores with cognitive function and future cognitive decline. British Journal of Ophthalmology, 0, , bjo-2022-322762. | 2.1 | 2 |
| 1111 | Directed Functional Brain Connectivity is Altered in Sub-threshold Amyloid-β Accumulation in Cognitively Normal Individuals. Neuroscience Insights, 2023, 18, 263310552311616. | 0.9 | 0 |
| 1112 | Tau positron emission tomography in tauopathies: A narrative review. Precision and Future Medicine, 2023, 7, 7-24. | 0.5 | 0 |
| 1113 | Predicting Dementia Risk Factors Based on Feature Selection and Neural Networks. Computers, Materials and Continua, 2023, 75, 2491-2508. | 1.5 | 2 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1114 | Stimulus material selection for the Dutch famous faces test for older adults. Frontiers in Medicine, 0, 10, . | 1.2 | 1 |
| 1115 | Navigation in individuals at risk for Alzheimer's disease. , 2024, , . | | 0 |
| 1116 | The Relationship between Whole-Grain Intake and Measures of Cognitive Decline, Mood, and Anxietyâ€"A Systematic Review. Advances in Nutrition, 2023, 14, 652-670. | 2.9 | 2 |
| 1127 | Mild cognitive impairment classification based on a deep learning-based approach using EEG data. , 2022, , . | | 0 |
| 1135 | RemÃ©diation cognitive enÂpsychiatrie du sujet Ã¢gÃ©. , 2023, , 439-465. | | 0 |
| 1147 | Application of Convolution Neural Network to Detect the Stages of Alzheimer Disease for Magnetic Resonance Imaging. , 2023, , . | | 0 |
| 1166 | Chronic Stress, Depression, and Alzheimerâ€™s Disease: The Triangle of Oblivion. Advances in Experimental Medicine and Biology, 2023, , 303-315. | 0.8 | 1 |
| 1181 | Epigenetic Therapy for Alzheimerâ€™s Disease. , 2023, , 199-217. | | 0 |
| 1182 | Lab-on-chip platform for neurodegenerative disorder. , 2024, , 197-219. | | 0 |
| 1197 | Three Neurodegenerative Diseases: A Single Hope. , 2023, , 1-25. | | 0 |
| 1199 | Image processing: an early detection tool for Alzheimerâ€™s disease. , 2024, , 99-136. | | 0 |
| 1208 | Physical activity interventions in cognitive aging. , 2023, , . | | 0 |
| 1215 | Active Transfer Learning forÂ3D Hippocampus Segmentation. Lecture Notes in Computer Science, 2023, , 224-234. | 1.0 | 0 |
| 1221 | Fuzzy Clustering to Asses BALI and LIBRA Factors for Estimation of DTI Measures. , 2023, , . | | 0 |
| 1222 | A Study on the Assisted Diagnosis of Alzheimer's Disease Based on JOINT ICA Algorithm. , 2023, , . | | 0 |
| 1226 | Community-Based Strategies to Reduce Alzheimerâ€™s Disease and Related Dementia Incidence Among Rural, Racially/Ethnically Diverse Older Adults. Current Geriatrics Reports, 2023, 12, 205-219. | 1.1 | 1 |
| 1230 | Glucose, glycolysis, and neurodegenerative disorders. , 2024, , 333-384. | | 0 |
| 1257 | Machine Learning and Deep Learning Techniques for Alzheimer's Disease Prediction Using CSF and Plasma Biomarkers. , 2023, , . | | 0 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1264 | Statistical significance maps based on machine learning. On the use of data-dependent upper bounds. , 2023, , . | | 0 |
| 1275 | Liquid–liquid phase separation in Alzheimer's disease. Journal of Molecular Medicine, 2024, 102, 167-181. | 1.7 | 0 |
| 1276 | Monitoring synaptic pathology in Alzheimer's disease through fluid and PET imaging biomarkers: a comprehensive review and future perspectives. Molecular Psychiatry, 0, , . | 4.1 | 0 |
| 1287 | Troubles neurocognitifs chroniques. , 2023, , 142-173. | | 0 |
| 1296 | Introduction to Neurodegenerative Diseases. Advances in Medical Diagnosis, Treatment, and Care, 2024, , 25-58. | 0.1 | 1 |
| 1300 | Epilepsy and epileptiform activity in late-onset Alzheimer disease: clinical and pathophysiological advances, gaps and conundrums. Nature Reviews Neurology, 2024, 20, 162-182. | 4.9 | 0 |